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Riassunto 
 
 
Negli ultimi decenni, sono aumentate le preoccupazioni scientifiche, il dibattito 
pubblico e l’attenzione dei media sui possibili effetti deleteri nell’ uomo e nell’ 
ambiente che possono derivare dall’ esposizione ad alcune sostanze in grado di 
interferire con il sistema endocrino. I composti perturbatori, o interferenti, endocrini 
(EDC) comprendono una varietà di classi di sostanze, tra cui ormoni naturali e 
sintetici, costituenti vegetali, pesticidi, sostanze utilizzate nell'industria e nei 
prodotti di consumo, sostanze inquinanti. È ben documentato che i target degli EDC 
sono principalmente i recettori nucleari (NR) come i recettori estrogenici (ER) tipici 
degli ormoni sessuali. Questo recettore ER è coinvolto sia in un ampio spettro di 
processi fisiologici che avvengono in diversi organi sia in diverse malattie, come il 
cancro della mammella e dell'endometrio, l'osteoporosi e l'ipertrofia della prostata, 
le malattie neurodegenerative o l'attivazione del sistema immunitario. Le agenzie 
deputate alla protezione della salute umana e dell’ambiente stanno affrontando la 
necessità di indagare e chiarire le modalità di azione di questi EDC mediante lo 
sviluppo di metodi tossicologici alternativi, come il modello in silico ed i saggi in 
vitro utili col fine di prevedere la tossicità di questi EDC. Il mio progetto di ricerca 
ha avuto l’ambizioso obiettivo di sviluppare una strategia tossicologica integrata 
basata sulla combinazione delle informazioni disponibili sull’ interferenza 
endocrina presenti in letteratura, sui saggi in silico, sulle metodologie di “imaging” 
applicate a sistemi di attivazione recettoriale in vitro, in vivo ed ex vivo con 
l’obiettivo di caratterizzare all’interno di un set di molecole quelle sostanze 
chimiche con attività di interferenza endocrina ma anche capaci di attivare altri 
percorsi tossicologici come l’infiammazione e lo stress ossidativo misurati nell'area 
 
 
genitale maschile ed addominale di topi maschi. Le molecole selezionate variano 
da interferenti endocrini noti (DES) a sospetti (BPA) e comprendono composti sia 
sintetici (DEHP) che naturali (genisteina). 
Il primo approccio utilizzato è stato l'analisi in silico con valutazione del possibile 
legame di queste sostanze al recettore alfa estrogenico per supportare l'ipotesi 
iniziale che l’attività ormonale di queste sostanze avviene attraverso un 
meccanismo recettoriale. Questo approccio è ampiamente utilizzato e fa anche parte 
del primo livello di indagine suggerito dall'EFSA / ECHA nel riconoscimento degli 
interferenti endocrini. La metodologia computazionale ha stimato diversi valori di 
affinità di ciascun ligando con il suo sito di legame nel recettore. L'uso di due diversi 
approcci (XP GLIDE SCORE e MMGBSA dG Bind) ha anche permesso di 
considerare la solvatazione. Ciò significa che il protocollo MMGBSA ha 
considerato l’interazione di alcune molecole di acqua con il sito di legame 
recettoriale ed anche l’interazione solvente-ligando. L'estradiolo ha mostrato i 
migliori valori di affinità in entrambi gli approcci, poiché essendo l'ormone 
endogeno, è stato in grado di contrastare l'effetto di solvatazione. 
I valori della costante di dissociazione (Ki) calcolati a partire da XP GLIDE SCORE 
si sono adattati bene con il saggio di legame determinato sperimentalmente in vitro 
da altri gruppi di ricerca. Pertanto, il Ki calcolato è stato scelto come parametro per 
la predizione della possibile attività di perturbazione (o interferenza) endocrina 
(IE). Tuttavia,  la mancanza di correlazione tra il Ki (calcolato e sperimentale) e 
l'attività IE osservata sperimentalmente in vivo (dati di letteratura) per tutte le 
sostanze chimiche (solo estradiolo e zearalenone hanno affinità simili a ER ed 
evidenze bibliografiche di attività di IE; genisteina ha buoni valori Ki ma non 
attività IE come BPA e metossicloro), non ha consentito la definizione di una 
priorità per l’attività di interferenza endocrina delle sostanze chimiche studiate 
attraverso il calcolo della loro affinità. 
Nel passo successivo per verificare se il legame del recettore fosse ben correlato 
con l'attività ormonale, è stato eseguito il test in vitro di attivazione del recettore 
estrogenico, basato sulla capacità di un composto di stimolare l'attività 
trascrizionale estrogeno-dipendente nelle cellule di mammifero geneticamente 
modificate. Le linee cellulari usate sono cellule MCF-7 che esprimono il recettore 
estrogenico endogeno. Le cellule sono trasformate (transfettate) introducendo 
vettori contenenti sequenze di DNA per il recettore, insieme agli ERE (elementi che 
 
 
rispondono all’estrogeno) legati a un gene “reporter” ed il gene “reporter” stesso. Il 
gene “reporter” utilizzato nelle cellule tumorali umane di solito codifica per 
l’enzima luciferasi (CALUX, espressione della luciferasi chimicamente attivata). 
Nel test di transattivazione gli EDC hanno mostrato la loro potenza estrogenica 
calcolata come EC50, rispetto al controllo positivo, il 17β-estradiolo. Questo 
sistema ci ha permesso di valutare la cinetica e le conseguenze biologiche 
dell’attivazione cellulare nello stesso strato di cellule mediante la cattura di 
immagini di bioluminescenza di emissioni di fotoni dell’attivazione recettoriale a 6 
e 48 ore dai trattamenti iniziali. Da questo saggio in vitro sono stati presi in 
considerazione tre fattori quali potenza, efficacia e tendenza nel tempo. 
L'attivazione dinamica in vitro del recettore estrogenico ha mostrato che per alcune 
sostanze chimiche (genisteina, BPA, metossicloro), la potenza (EC50) e l'efficacia 
(induzione delle pieghe) sono cambiate nel tempo, ma non per altri (estradiolo, 
zearalenone e DES). Considerando che 17β-estradiolo, zearalenone e DES hanno 
certamente un'attività nell'animale e nell'uomo come interferenti endocrini, la 
durata del parametro effetto combinato con la potenza e l'efficacia si è mostrato 
utile nel predire l'attività ormonale. Insieme all'affinità del recettore e alla capacità 
di indurre una risposta biologica, esso è sembrato anche importante determinare 
quanto la risposta potesse essere sostenuta nel tempo. Di conseguenza, la 
combinazione della variazione della potenza e dell'efficacia, "normalizzata" rispetto 
ai valori di efficacia quantificati a 48 ore, è stata utilizzata con successo nella 
discriminazione di composti positivi e negativi per la loro attività di interferente 
endocrino. Per mezzo di questa analisi estradiolo, DES e zearalenone sono stati 
messi in cima alla lista (supportati anche dalla loro nota attività di IE), la genisteina 
è risultata rappresentare una presunta soglia di non-preoccupazione per l'effetto IE, 
in supporto dei dai di letteratura), mentre il metossicloro e il BPA non sono stati 
considerati priorità in termini di attività di IE. Questa classifica in vitro ha mostrato 
una correlazione con i risultati del modello in silico, poiché i composti più forti nel 
legarsi al recettore estrogenico sono stati classificati nelle prime posizioni 
(estradiolo, DES e zearalenone). Inoltre, non è stato possibile calcolare i valori di 
EC50s per il 4-nonilfenolo, DEHP e vinclozolin, di conseguenza non è stato 
possibile classificarli come IE, che totalmente in accordo con i risultati in silico ed 
in linea con i dati di letteratura (vinclozolin è principalmente un’antagonista 
androgenico). Il terzo approccio della nostra procedura è stato condotto per 
 
 
verificare in vivo l'interazione delle sostanze chimiche selezionate con il recettore 
degli estrogeni ma anche l’attivazione di altri percorsi che innescano effetti primari 
nocivi. Abbiamo utilizzato tre topi transgenici progettati per valutare l'effetto dei 
composti nell’attivare il recettore estrogenico e/o causare stress ossidativo ed 
infiammazione. Abbiamo scelto di testare lo zearalenone (noto interferente 
endocrino e chiaramente identificato come tale dal nostro approccio in silico-in 
vitro) e il BPA per il quale esistono dati controversi in letteratura e che il nostro 
approccio ha già classificato come non IE. Nei nostri esperimenti, lo zearalenone 
ha dimostrato di essere attivo sulla via estrogenica nella zona addominale e ha 
attivato in modo significativo la via infiammatoria nei genitali (in questo caso 
specifico nella prostata, risultato di analisi di bioluminescenza ex vivo). Questi 
risultati sono risultati perfettamente in linea con i dati della letteratura, in cui 
l'infiammazione e metaplasia della prostata sono state rilevate sia nei topi che nei 
ratti. Il bisfenolo A non ha prodotto un'attivazione significativa in entrambe le aree 
e nell'analisi ex vivo, sempre in accordo con i nostri risultati in silico / in vitro. 
La mancanza dell'attivazione del recettore estrogenico dell’area genitale da parte 
dell'estradiolo è stata probabilmente dovuta alla somministrazione orale del 
composto tramite l'acqua potabile. Questo composto è noto per esercitare potenti 
effetti avversi negli studi tossicologici quando somministrato per iniezione, ma la 
nostra intenzione è stata quella di indagare gli effetti IE per via orale che è 
considerata rilevante per l'esposizione umana. Quindi abbiamo usato una 
combinazione di approcci innovativi che hanno portato alla conclusione che lo 
screening in silico non può essere usato come procedura autonoma a causa della 
sua intrinseca mancanza di significato biologico, sebbene possa essere usato con 
successo come primo passo per la definizione delle priorità in un approccio di 
livello. Il secondo controllo obbligatorio per i risultati positivi in silico dovrebbe 
essere una procedura di valutazione in vitro, in cui l'affinità dei composti positivi 
viene misurata attraverso un test cellulare di riferimento. I nostri risultati hanno 
mostrato che integrando la variabile temporale nella valutazione della potenza e 
dell’efficacia, i composti testati possono essere classificati come IE o no-IE. Mentre 
l'esperimento in vivo ha evidenziato che un potente composto estrogenico, come lo 
zearalenone, potrebbe anche destare preoccupazione per l'attivazione di altre vie 
tossicologiche come quelle infiammatorie. 
 
 
Siamo consapevoli che questa proposta di procedura debba essere valutata e 
validata su dozzine di molecole la cui attività in vivo è già nota, prima di arrivare 
al suo utilizzo per predire la possibile attività di IE di molecole sconosciute, ma è 
importante che questo approccio meriti di essere implementato. 
 
 
 
Abstract 
 
In the last two decades, there have been growing scientific concern, public debate, 
and media attention over the possible deleterious effects in humans and wildlife that 
may result from exposure to substances that have the potential to interfere with the 
endocrine system. Endocrine disrupting compounds (EDCs) encompass a variety 
of substance classes, including natural and synthetic hormones, plant constituents, 
pesticides, substances used in industry and in consumer products, pollutant. It is 
well documented that EDCs targets are mainly the nuclear receptors (NRs) such as 
the sexual hormones estrogen receptors ERs. ER is involved in a broad spectrum of 
physiological processes in different organs and tissues as well as in several diseases, 
such as breast and endometrial cancer, osteoporosis, and prostate hypertrophy, 
neurodegenerative diseases or in immune system activation. The regulatory 
agencies for the protection of human health and wildlife have been issuing the 
necessity to investigate and clarify the mode of action of these exogenous 
substances by the development of alternative toxicological methods such as in silico 
model and in vitro testing in order to predict the toxicity of these EDCs. This 
research had the ambitious aim to develop an integrated toxicological strategy based 
on the combination of available information of endocrine disrupting activity 
retrieved from the scientific literature, in silico model, imaging methodologies 
applied to reporter systems in vitro and in vivo and ex vivo to predict among a set 
of chemicals those with an endocrine disrupting activity or ability to activate other 
toxicological pathways such as inflammation and oxidative stress measured in the 
male reproductive organs and in the genital and abdominal area of mice. The 
 
 
selected molecules range from known (DES) to suspected (BPA) endocrine 
disruptors and included both synthetic (DEHP) and natural (genistein) compounds. 
The first step used was in silico analysis with evaluation of the possible binding of 
selected substances to the estrogen alpha receptor to support the hypothesis that 
their hormonal activity occurred through a receptorial mechanism. This approach 
is commonly used and is also part of the first level of investigation suggested by 
EFSA/ECHA in the recognition of EDCs. The computational methodology 
estimated different values of affinity of each ligand to hER Ligand Binding Domain 
(LBD). The use of two different approaches (XP GLIDE SCORE and MMGBSA 
dG Bind) also allowed for solvation to be taken into account. That meant that 
MMGBSA protocol considered both the interactions of some water molecules with 
the LBD and the solvent-ligand ones. The estradiol showed the best affinity values 
in both approaches as being the endogenous hormone was able to contrast the 
solvation effect. The dissociation constant (Ki) values calculated from the XP 
GLIDE SCORE fitted well with the Ki experimentally determined in vitro binding 
assay by other research groups. Thus, the computed Ki has been chosen as 
parameter for the prediction of putative endocrine disruptor activity. However, the 
lack of correlation between the (computed and experimental) Ki and in vivo 
experimental observed ED activity (from literature data) for all chemicals (only 
estradiol and zearalenone have similar affinity to ER and literature evidences of ED 
activity; genistein has a good Ki values but not ED activity such as BPA and 
methoxychlor), did not allow a prioritization of the investigated chemicals for ED 
activity through the results of their affinity. In the next step, to check if the receptor 
binding well correlated with the hormonal activity, the ER Reporter gene assay was 
performed, based on the ability of a compound to stimulate ER-dependent 
transcriptional activity in genetically engineered mammalian cells. The cell lines 
are MCF-7 cells which express human endogenous ERα. The cells are transformed 
(transfected) by introducing vectors containing DNA sequences for the receptor, 
along with EREs linked to a reporter gene, and the reporter gene itself. The reporter 
gene used in human cancer cells usually codes for luciferase (CALUX, chemically 
activated luciferase expression). In the transactivation the EDCs show their 
estrogenic potency calculated as EC50, in respect to the positive control, 17β-
estradiol. This system has enabled us to evaluate the kinetic and the biological 
consequences of cellular activation in the same cell monolayer by bioluminescence 
 
 
imaging of photon emissions that were pictures of activated ER status at 6 and 48 
hours after the initial treatments. From this in vitro assay three factors were taken 
into consideration, power, efficacy and trend over time. The in vitro dynamic ER 
activation showed that for some chemicals (genistein, BPA, methoxychlor), the 
potency (EC50) and the efficacy (fold induction) changed over time, but not for 
others (estradiol, zearalenone and DES).  
Considering that estradiol, zearalenone and DES certainly have an activity in the 
animal and in man as endocrine disruptors, the duration of effect parameter 
combined with power and efficacy were likely to be associated in predicting the 
activity. Together with receptor affinity and the ability to induce a biological 
response, it also seemed relevant how long the response was lasting. By 
consequence, the combination of the variation of the potency response and the 
efficacy, “normalized” respect to the efficacy values quantify at 48 hours, was 
successfully used in discriminating positive and negative compounds for their 
endocrine disrupting activity. By means of this analysis 17β-estradiol, DES and 
zearalenone were put at the top of the list (also supported by their known ED 
activity), genistein resulted to represent a putative threshold of no-concern for ED 
effect, in supporting published data, while methoxychlor and BPA were definitely 
not considered a priority in terms of ED activity. This in vitro classification fitted 
well with the in silico outcomes, since the strongest estrogen receptor binders were 
ranked in the first positions (17β-estradiol, DES and zearalenone). Besides, was no 
possible to calculate EC50s for 4-nonylphenol, DEHP and vinclozolin, not making 
possible to classify them as ED, totally in agreement with in silico results and in 
line with literature data (vinclozolin is mainly an androgen antagonist). The third 
step of our stepwise approach was intended to verify in vivo the interaction of 
selected chemicals with the estrogen receptor and in addition the activation of their 
pathways triggering primary harmful effects. We used three reporter mice designed 
in order to evaluate the effect of selected compounds to activate ER and causing 
oxidative stress and inflammation. We have chosen to test zearalenone (well-known 
endocrine disruptor and clearly identified as such by our in silico-in vitro approach), 
and BPA for which there are controversial data in the literature and that our 
approach has negatively classified as ED. In our experiments zearalenone showed 
to be active on ER pathway in the abdominal area and significantly activated the 
inflammatory pathway in the genitals (in this specific case in the prostate, result of 
 
 
ex vivo bioluminescence analysis). These results were perfectly in line with the 
literature reports, in which prostate inflammation and metaphase were detected in 
both mice and rats. Bisphenol A did not produce a significant activation in both the 
areas and in the ex vivo analysis, again in agreement with in silico/in vitro results. 
We used a combination of innovative approaches that led to a conclusion that in 
silico screening cannot be used as a stand-alone procedure due to its intrinsic lack 
of biological meaning, although it can be successfully used as a first prioritizing 
step in a tier approach. The second mandatory check for the in silico positive hits 
should be an in vitro evaluation procedure, in which the affinity of the positive hits 
is measured through a reference cellular assay. Our results showed that integrating 
the time variable in the evaluation of the potency, the tested compounds could be 
classified as ED or no-ED. The in vivo experiment highlighted that a potent 
estrogenic compound, as zearalenone, could also raise concern for the activation of 
other toxicological pathway such as the inflammatory ones. 
We are aware that this indication of procedure must be evaluated and validated on 
dozens of molecules whose in vivo activity is already known before arriving at its 
use to predict the possible activity of ED of unknown molecules, but we think that 
this approach deserves to be implemented. 
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Chapter 1 
1.1 Introduction 
 
In the last two decades, there have been growing scientific concern, public debate, 
and media attention over the possible deleterious effects in humans and wildlife that 
may result from exposure to substances that have the potential to interfere with the 
endocrine system. The endocrine system is a communication system that maintains 
normal physiological balance across multiple organ systems. It accomplishes this 
by modulating or regulating the activity of almost everybody system in reaction to 
variations in body temperature, activity level, stress, and circulating levels of 
nutrients and hormones required for growth, reproduction, and metabolism. 
Substances which interfere with the endocrine system are endocrine modulators or 
endocrine disruptors, depending on the final effect on the whole organism. The 
latter term has been defined in Weybridge in the 1996 and has been slightly 
modified by WHO in the 2002: ‘‘An endocrine disruptor is an exogenous substance 
or mixture that alters function(s) of the endocrine system and consequently causes 
adverse health effects in an intact organism, or its progeny, or (sub)populations’’. 
Endocrine disrupting compounds (EDCs) encompass a variety of substance classes, 
including natural and synthetic hormones, plant constituents, pesticides, substances 
used in industry and in consumer products, and other industrial by-products and 
pollutants [1, 2]. The target of EDCs is mainly the nuclear receptors (NRs) such as 
the sexual hormones receptors (estrogen receptors, ERs and androgen receptors, 
ARs). These are ligand-activated transcriptional factors belonging to the super 
family of nuclear receptors. ERs are present as two receptor subtypes, ERα and ERβ 
[3]. ERs mediate a broad spectrum of physiological processes in different organs 
and tissues as well as a range of diseases, such as breast and endometrial cancer, 
osteoporosis, and prostate hypertrophy. Recently, estrogens and their receptors 
have also been implicated in cardiovascular and central nervous system disorders 
[4] or in immune system activation [5]. The regulatory agencies for the protection 
of human health and wildlife have been issuing the necessity to investigate and 
clarify the mode of action of these exogenous substances by the development of 
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alternative toxicological methods such as in silico model and in vitro testing in order 
to predict the toxicity of these EDCs to human health and wildlife. 
 
 
1.2 Endocrine system: hormones & receptors 
 
The endocrine system represents a complex network system of glands, hormones 
and receptors, which play a critical function by maintaining, for example, the 
normal physiological balance, growth, reproduction, development, metabolism [2]. 
It acts through the actions of molecules called hormones which are produced by 
endocrine glands such as pituitary gland at the base of the brain, the thyroid gland 
in the neck, the adrenal glands in the abdominal next to the kidneys, the gonads and 
certain parts of the pancreas (Figure 1). The hormones are grouped in four structural 
classes (Table 1): protein and peptide hormones such insulin; steroids that derive 
from cholesterol (Figure 2) as estrogen, testosterone, mineralocorticoids, vitamin 
D; tyrosine or tryptophan derivates such catecholamines, thyroid hormones, 
serotonin; eicosanoid as prostaglandins, prostacyclin, thromboxane [6]. 
These hormones (Table 1) are chemical messengers that travel through the 
bloodstream to produce effects on distant cells and tissues. 
For example, reproductive hormones, steroids (estrogens, androgens, progestins) 
and proteins (LH and FSH) control the complex reproduction physiological 
processes, the thyroid hormones (TSH, T3 and T4) are involved in the metabolic 
processes then in the appetite and body weight regulation and brain development. 
In addition to their actions on these physiological processes, all hormone systems 
are governed in such way so that hormone levels are at the appropriate 
concentration in blood to be effective at physiological process [2]. 
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Hormones exert their activities by specific interaction with some proteins called 
receptors which have a widespread expression in all body tissues or outside - inside 
the cells.  
Generally, hormones act at very low concentrations because of its specificity and 
selectivity to bind to receptor while at higher concentration could cause a 
downregulation of receptor number [2; 7]. In addition to this mechanism, higher 
concentration of hormones can cause increased of cytotoxicity of receptor 
expression with the consequence of low hormonal response. For example, the 
MCF7 breast cancer cell lines proliferate in response to estrogen until the high doses 
(10-5 – 10-4 M) produce cytotoxicity. The same toxicity has been observed in a 
Figure 1. Overview of endocrine system and hormones. Figure from the 
report “State of the Science of Endocrine Disrupting Chemicals – 2012” [2] 
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subpopulation of MCF7 cells that no longer express the estrogen receptor, 
suggesting that 17β-estradiol (the natural endogenous estrogen) has not an 
endocrine effect at high doses, but it has a general toxicity [2]. 
Most of these receptors belongs to nuclear receptor family. Nuclear receptors (NRs) 
are members of a large superfamily of evolutionarily related transcription factors 
that control a plethora of biological processes. are modular proteins organized into 
three major functional domains, namely (i) a variable and intrinsically unfolded N-
terminal A/B domain harboring the transcriptional activation function 1 (AF-1), (ii) 
a conserved DNA-binding domain (DBD), and (iii) a C-terminal ligand-binding 
domain (LBD) hosting the activation function 2 (AF-2) (Figure 3) [3; 8]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Pathways for the synthesis of human sex and adrenal steroids under the 
specific enzyme regulation common to both sexes. P450scc = Cholesterol side-chain 
cleavage enzyme; 3-βHSD = 3β-Hydroxysteroid dehydrogenase/Δ5-4 isomerase; 
P45017α = 17 alpha-hydroxylase = 17, 20 lyase; 17- β HSD = 17β-Hydroxysteroid 
dehydrogenases; P450c21 = 21-hydroxylase; P450aldo = aldosterone synthase; P450c11 
= Steroid 11β-hydroxylase; P450arom = aromatase; 5α-reductase. 
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1.3 Estrogen receptor 
 
Estrogens like other steroid hormones, are naturally occurring 
cyclopentanophenanthrene compounds whose synthesis begins with cholesterol. 
The most potent and dominant estrogen in humans is 17β-estradiol (E2), but lower 
levels of the estrogens estrone and estriol are also present. 17β-Estradiol (E2) 
controls many aspects of human physiology, including development, reproduction 
and homeostasis, through regulation of the transcriptional activity of its cognate 
receptors (ERs) [4; 9]. The estrogen receptors exist in two subtypes, ERα and ERβ 
(Figure 4). ERs mediate a broad spectrum of physiological effects in different 
organs and tissues and are involved in a range of diseases, such as breast and 
endometrial cancer, osteoporosis, and prostate hypertrophy. Recently, estrogens 
and their receptors have also been implicated in cardiovascular and central nervous 
system disorders [4] or in immune system activation [5]. The biological cascade of 
events reacted by interaction with a ligand (xenobiotics or endogenous substances) 
causes that NRs undergoes dimerization and translocation to the respective HRE in 
the nucleus. Then transcriptional activity follows, as modulated by co-regulators, 
through recruitment of transcription factors and RNA polymerase to the initiation 
site. Thus, there is the synthesis of mRNA which released into cytoplasm (Figure 
3) [8]. 
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ERα and ERβ synthesis are under the transcriptional activity of two separate genes, 
ESR1 and ESR2, respectively, present on distinct chromosomes: locus 6q25.1 and 
locus 14q23-24.1, respectively (Figure 4). Both receptors have a different 
widespread tissue distribution. ER α is mainly expressed in uterus, ovary, prostate, 
testis (Leydig cells), epididymis, brain, thymus, bladder, kidney, liver. ER β is 
predominantly distributed colon, prostate (epithelium), testis, ovary (granulosa 
cells), bone marrow, salivary gland, vascular endothelium, and certain regions of 
the brain [4; 9; 10].  
The ERα subunit is largely studied as pharmaceutical target [11; 12] and in 
toxicological field to understand the mechanism of action of endocrine disruptor 
compound (EDCs) [2; 10; 13]. 
 
 
 
Figure 3. Depicted schema representing structural domains 
generally harbored by NRs, in addition to their canonical 
downstream functionality. Upon binding to activating ligand, NRs 
undergo dimerization and translocation to the respective HRE in 
the nucleus. Transcriptional activity follows, as modulated by co-
regulators, through recruitment of transcription factors and RNA 
polymerase to the initiation site. CoR, corepressor; Lig, activating 
ligand; RNA pol, RNA polymerase; general regions shared by all 
NRs labeled in parentheses (A–E) within domains (from El 
Hokayem et al., 2017 [8]). 
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1.4 Endocrine disruptors: definition 
 
Interaction of chemicals with endocrine system may lead to changes that are 
transient, where the control mechanisms of endocrine systems will compensate for 
chemically-induced effects; or may cause permanent changes that may then lead to 
adverse effects. In the latter situation, a chemical may be an endocrine disruptor 
(ED). By consequence, substances which interfere with the endocrine system are 
endocrine modulators or endocrine disruptors, depending on the final effect on the 
whole organism. The latter term has been defined in Weybridge in the 1996 [1] and 
has been slightly modified by WHO in the 2002: ‘‘An endocrine disruptor is an 
exogenous substance or mixture that alters function(s) of the endocrine system and 
consequently causes adverse health effects in an intact organism, or its progeny, or 
Figure 4. Genomic format, domain structure, and common splice 
variants of human ERα (A) and ERβ(B). Both ERα and ERβ gene are 
comprised of eight exons interrupted by long introns. The common 
splice variants of both ERa and ERb exhibit in-frame deletion of exon 
3 (R E3), exon 4 (R E4) or both (R E3-4), with an exception of intron 
coding insertion, ERb2, which bears 18 amino acids insertion in the 
LBD compared to full-length ERb (from Ascanzi et al., 2006 [9]). 
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(sub)populations’’ [2]. This definition refers to different group of chemicals such 
as home-made substance, pesticide, synthetic hormones, plant constituents, 
pesticides, pollutants.  
EDCs can affect the endocrine systems and cause adverse effects by several 
mechanisms: 
• by mimicking the biological activity of an endogenous hormone by binding 
to a cellular receptor, leading to an unwanted response by initiating the 
cell’s normal response to the naturally occurring hormone at the wrong time 
or to an excessive extent (agonistic effect); 
• by binding to the receptor without any activation and blocking the binding 
of the natural hormone (antagonistic effect); 
• by binding to transport proteins in the blood, thus altering the amounts of 
natural hormones that are present in the bloodstream; 
• by interfering with the metabolic processes in the body, affecting the 
synthesis or breakdown rates and release of the natural hormones [14]; 
EDCs exert mainly their activity towards the interaction with nuclear 
receptor [2]. 
 
1.5 Biological implication of endocrine disruptor compounds  
 
The EDCs show several characteristics: 
• act at low doses 
• bioaccumulate 
• produce a non-linear dose response curve, high dose effects are not same 
as low dose. 
The effect is always dependent on mechanism of action, the target tissue and the 
specific life - stage of exposure (Figure 5) [2]. 
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Figure 5. Example of EDCs mechanism and exposure window (figure from [2]) 
 
 It is well documented that animals and humans exposed in utero or perinatally to 
the potent synthetic estrogen diethylstilbestrol (DES), developed reproductive 
adversity (e.g., reduced sperm counts, reproductive tract malformations), tumours 
to reproductive tract, and other endocrine-related endpoints [15; 16].  
Chemicals that modulate endocrine signaling pathways are widespread in the 
environment or they occur naturally (e.g., phytoestrogens), and they are 
synthetically produced for a variety of uses, including pesticides in agriculture, 
polymers used in food packaging materials, etc... Despite the evidence of 
correlation between the exposure to pharmacological doses of DES during the 
critical developmental time points and the adverse effects in humans has been 
clearly defined, the evidence between the exposure to low concentration of a weaker 
hormonally active chemical and the toxicity in humans has not been clearly 
documented [17]. 
 
1.6 Regulatory perspective and toxicological 
characterization (in silico, in vitro and in vivo testing) 
 
Regulatory bodies for the protection and safety of consumer health and environment 
such as ECHA, EFSA, EPA etc. have been facing the endocrine disruptor problem 
by issuing severe regulations. Indeed, according to Regulation EC No. 1107/2009 
relative to Plant Protection Product, no PPP could be place on the market if “An 
active substance, safener or synergist shall only be approved if, on the basis of the 
assessment of Community or internationally agreed test guidelines or other 
available data and information, including a review of the scientific literature, 
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reviewed by the Authority, it is not considered to have endocrine disrupting 
properties that may cause adverse effect in humans, unless the exposure of humans 
to that active substance, safener or synergist in a plant protection product, under 
realistic proposed conditions of use, is negligible, that is, the product is used in 
closed systems or in other conditions excluding contact with humans and where 
residues of the active substance, safener or synergist concerned on food and feed 
do not exceed the default value set in accordance with point (b) of Article 18(1) of 
Regulation (EC) No 396/2005”. 
Under the Regulations No 1907/2006 REACH (Registration, Evaluation and 
Authorization of Chemicals) a chemical identified as endocrine disruptor activity is 
ruled out by the article 57 (f) of SVHC. 
To identify this toxicological profile ECHA and EFSA have issued a guidance 
“Guidance for the identification of endocrine disruptors in the context of 
Regulations (EU) No 528/2012 and (EC) No 1107/2009” based also on OECD 
(Organization for Economic Co-operation and Development) framework 
“Guidance Document 150 on Standardized Test Guidelines for Evaluating 
Chemicals for Endocrine Disruption, revised 2018” [18;19] (Table 1). 
 
 
Table 1. Conceptual framework for testing and assessment of endocrine disrupters [19] 
Mammalian and Non-Mammalian Toxicology 
Level 1 
Existing data 
• Physical & chemical properties, e.g., MW reactivity, volatility, biodegradability. 
• All available (eco)toxicological data from standardized or non-standardized tests. 
• Read across, chemical categories, QSARs and other in silico predictions, and ADME model predictions. 
Level 2 
In vitro assays providing data about selected endocrine mechanism(s) / pathways(s) (Mammalian and non-mammalian methods) 
• Estrogen or androgen receptor binding affinity (OECD TG 493). 
• Estrogen receptor transactivation (OECD TG 455 & TG 457). 
• Androgen transactivation assay (OECD TG 458). 
• Steroidogenesis in vitro (OECD TG 456). 
• MCF-7 cell proliferation assays (ER ant/agonist). 
• Other assays as appropriate. 
Mammalian and Non-Mammalian Toxicology Mammalian and Non-Mammalian Toxicology 
Level 3 
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In vivo assays providing data about selected endocrine mechanism(s) / pathway(s) 
• Uterotrophic assay (OECD TG 440). 
• Hershberger assay (OECD TG 441) 
• Xenopus embryo thyroid signaling assay (When/if TG is 
available). 
• Amphibian metamorphosis assay (OECD TG 231). 
• Fish Reproductive Screening Assay (OECD TG 229). 
• Fish Screening Assay (OECD TG 230). 
Androgenized female stickleback screen 
(OECD ). 
Level 4 
In vivo assays providing data on adverse effects on endocrine relevant endpoints 
• Repeated dose 28-day study (OECD TG 407). 
• Repeated dose 90-day study (OECD TG 408). 
• 1-generation reproduction toxicity study (OECD TG 
415). 
• Male pubertal assay (see GD 150, Chapter C4.3). 
• Female pubertal assay (see GD 150, Chapter C4.4). 
• Intact adult male endocrine screening assay (see GD 
150, Chapter Annex 2.5). 
• Prenatal developmental toxicity study (OECD TG 414). 
• Chronic toxicity and carcinogenicity studies (OECD TG 
451-3). 
• Reproductive screening test (OECD TG 421). 
• Combined 28-day/reproductive screening assay 
(OECD TG 422). 
• Developmental neurotoxicity (OECD TG 426). 
• Fish sexual development test (OECD TG 234). 
• Fish Reproduction Partial Lifecycle Test (when/If TG is 
Available). 
• Larval Amphibian Growth & Development Assay (OECD TG 241). 
• Avian Reproduction Assay (OECD TG 206). 
• Mollusc Partial Lifecycle Assays (OECD TG 242 & TG 243). 
• Chironomid Toxicity Test (TG 218 & TG 219). 
• Daphnia Reproduction Test (with male induction) (OECD TG 
211). 
• Earthworm Reproduction Test (OECD TG 222). 
• Enchytraeid Reproduction Test (OECD TG 220). 
• Sediment Water Lumbriculus Toxicity Test Using Spiked 
Sediment (OECD TG 225). 
• Predatory mite reproduction test in soil (OECD TG 226). 
• Collembolan Reproduction Test in Soil (OECD TG 232). 
Level 5 
In vivo assays providing more comprehensive data on adverse effects on endocrine relevant endpoints over more extensive parts of 
the life cycle of the organism 
• Extended one-generation reproductive toxicity study 
(OECD TG 443). 
• 2-Generation reproduction toxicity study (OECD TG 
416). 
• FLCTT (Fish LifeCycle Toxicity Test) (when TG is available). 
• Medaka Extended One Generation Reproduction Toxicity Study 
Test (OECD TG 240). 
• Avian 2 generation reproductive toxicity assay (when TG is 
available). 
• Mysid Life Cycle Toxicity Test (when TG is available). 
• Copepod Reproduction and Development Test (when TG is 
available). 
• Sediment Water Chironomid Life Cycle Toxicity Test (OECD TG 
233); 
• Mollusc Full Lifecycle Assays (when TG is available). 
• Daphnia Multigeneration Assay (if TG is available). 
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1.7 3Rs in hazard assessment 
 
 
Furthermore, Regulatory agencies worldwide and scientific research stakeholders 
as European Union Reference Laboratory for alternatives to animal testing (EURL-
ECVAM) or Interagency Coordinating Committee on the Validation of Alternative 
Methods (ICCVAM) have also supporting the development of new strategies in the 
chemical risk assessment based on alternative toxicological testing methods to 
laboratory animals. According to that it was created the Adverse Outcome 
Pathways (AOP) that is an analytical construct that describes a sequential chain of 
causally linked events at different levels of biological organization that lead to an 
adverse health or ecotoxicological effect (Fig.6). AOPs are the central element of a 
toxicological knowledge framework being built to support chemical risk 
assessment based on mechanistic reasoning [20; 21].
 
Figure 6. Adverse Outcome Pathway conceptual framework [20]. 
 
In addition to have a quickly and reduced testing cost characterization of chemical 
profilers, also for endocrine disruptor toxicity, several computational or in silico 
methods have been developed. Benfenati et al [22] drafted a report where they 
explain what those new approaches are: “In the broad sense of the term, in silico 
models refer to computer tools and models available to scientists to simulate 
biological processes for a range of applications, species and level of biological 
organization (cellular, molecular, species, population, ecosystem, landscape etc.). 
In toxicology and risk assessment, in silico tools often aim to predict toxicity of 
chemicals and cover a wide range of methodologies that would also comprise 
molecular modelling approaches and general computational toxicology tools, 
including theoretical models based on the intrinsic structural and physicochemical 
properties of chemicals and rule-based expert systems. Structure-Activity 
 13 
 
Relationships (SAR) and Quantitative Structure Activity Relationships (QSAR) 
models are often collectively referred to as (Q)SAR as mathematical models that 
relate the structure of chemicals to their biological activities. The term 
‘quantitative’ refers to the fact that the molecular descriptors are quantifiable on a 
continuous scale and thus provide a quantitative relationship with toxicity (which 
may itself be expressed in quantitative or categorical terms). Molecular descriptors 
of chemicals include their inherent physicochemical properties (i.e. atomic 
composition, structure, sub-structures, hydrophobicity, surface area charge, and 
molecular volume). ….. SAR and QSAR models can provide a fast method for the 
toxicity screening of untested substances, for identifying emerging chemicals in the 
food chain that have not yet been tested for their safety to human health or the 
environment. They are typically used in combination with other non-testing (e.g. 
read-across) and testing (e.g. in vitro) methods in the context of integrated testing 
strategies (ITS) and Weight-of-Evidence assessments (EFSA, 2014). Read-across 
represents ‘a technique for predicting endpoint information for one substance 
(target substance), by using data from the same endpoint from (an)other 
substance(s), (source substance(s)’ as defined by the European Chemical Agency 
(ECHA) (ECHA, 2008). ECHA used two key approaches for read across: 1. 
Analogue approach for which read-across is applied within a group of a very 
limited number of substances e.g. simplest read-across from a single source 
substance to a target substance; 2.Category approach for which compounds can be 
grouped in the case of a high number of substances and comprehensive guidance 
on grouping and read-across has been published by the OECD (OECD, 2007) and 
ECHA (ECHA, 2008). Examples of criteria to group chemicals include physic-
chemical properties, functional/mechanistic/structural alert groups, chemical 
similarity …. The development of QSAR and read-across approaches for predicting 
toxicity of chemicals ideally involves quantitative understanding and data relating 
both toxicokinetic and toxicodynamic processes and some of the underlying 
parameters as predictor variables consider TK (e.g. partitioning coefficients) or 
TD (e.g. electronic properties) in the QSARs modelling. Key databases for QSAR 
and read-across have been described elsewhere (EFSA, 2014) and include: -The 
OECD QSAR Toolbox (http://www.qsartoolbox.org/) as a hazard identification tool 
which contains QSAR relationship methodologies to group chemicals into 
categories sharing the same structural characteristics and/or MoA. -The VEGA 
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platform (www.vega-qsar.eu) includes many models including physicochemical 
properties, ecotoxicological and toxicological properties ….. Key QSAR software 
and models used by international and national organizations including the Toxicity 
Estimation Software Tool (TEST), the OECD QSAR toolbox models and High-
throughput Virtual Molecular Docking (HTVMD), MetaCore, DEMETRA, 
CAESAR, DEREK, METEOR, Multicase, PASS, OASIS Times” [22]. 
In addition to QSAR models, new computational methods have generated to better 
investigate the behaviour of ligand (toxicant or drug) at the target level (e.g. proteins 
or nucleic acids). Then two computational structural biology techniques have 
developed as the molecular docking of ligands (e.g. toxicants) with their biological 
receptors or targets (e.g. proteins or nucleic acids); and the molecular dynamics 
(MD) simulations of ligand–receptor complexes compared with receptors alone. 
Molecular docking tool enable us to determine the best pose, in term of orientation 
and unique conformations, of ligand at the binding site and to assess the value of 
affinity of this specific and unique interaction. The best pose is computed by 
docking algorithms which employ distinct sampling techniques to identify 
energetically favourable ligand poses. The most commonly used sampling 
techniques are genetic algorithms, Monte Carlo techniques, and matching 
algorithms. While the assessment of affinity is generated by application of scoring 
function which comprises mathematical models that approximate the non-covalent 
binding energy of a ligand pose within the binding cavity of the receptor. 
This approach allows us to screen receptor–ligand interactions. These models have 
resulted in some advantages such as they are firstly inexpensive; it is possible to 
high throughput screen wide number of chemicals against a single target receptor 
(classical docking) or multiple target receptors against a single ligand (inverse 
docking); also to rapidly identify new ligand-binding sites within a receptor; the 
identified ligand poses can be scored in vacuo or in implicit solvent to obtain 
theoretical binding affinities; the results can be combined with pharmacophore 
mapping, shape-matching and molecular dynamic simulations to further investigate 
the nature and structural basis for a ligand– receptor interaction. While the possible 
disadvantages are the potential identification of incorrect binding site or target 
especially in the case of novel or previously uncharacterized xenobiotics; unreliable 
or misleading outcome when used with ligands that covalently modify their target 
receptor(s) [23]. 
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The biological mechanisms of EDCs have been broadly characterized by using cell 
culture system. OECD (reported Table 1, Level 2 above) and ICCVAM [13] have 
issued some guidelines for testing in a good reliability way such chemicals for 
endocrine disrupting activity while a large number of works have been showing the 
action of EDCs at cellular level, mainly towards nuclear receptors, estrogen and 
androgen ones [24; 25]. 
Considering the family of estrogen receptor Kuiper and co-workers investigated for 
the first time the ligand binding affinity of ERα and ERβ separately. In their work 
they found it out that for the physiological estrogens, the order of competition was 
17β-estradiol > estrone, 17a-estradiol (ERα) > estriol > catechol estrogens, 17α-
estradiol (ERβ)> estrone-3-sulfate. While different orders of competition were 
found: diethylstilbestrol > hexestrol > dienestrol > (E2) for ERα and dienestrol > 
diethylstilbestrol > hexestrol > (E2) for ERβ. In the same research of Kuiper, it was 
shown that genistein and coumestrol, two plant-derived nonsteroidal compounds, 
had a higher estrogenic affinity to ERβ, previously discovered by Kuiper [26], than 
ERα [10]. 
Different in vitro test have been developed and used to characterize the estrogenic 
like property of chemicals including competitive ER binding assay that measure the 
ability of test compound to compete with radiolabelled 17β-estradiol for binding to 
ER [10]; the E-screen assay that is a cell proliferation assay done with MCF-7 breast 
cancer cell lines, where it is quantified the increased cell number after treatment 
with the chemical [27] but it showed a disadvantage because of its lack of estrogen 
specificity; ER Reporter gene assays which is based on the ability of a compound 
to stimulate ER-dependent transcriptional activity in genetically engineered 
mammalian cells. The cell lines are T47D cells or MCF-7 cells which express 
endogenous ER or yeast cells or HeLa cells which have not endogenous ER. In both 
case the cells are transformed (transfected) by introducing vectors containing DNA 
sequences for the receptor, along with EREs linked to a reporter gene, and the 
reporter gene itself. The reporter gene used in human cancer cells usually codes for 
luciferase (CALUX, chemically activated luciferase expression) and the reporter 
gene used in yeast cells usually codes for β-galactosidase [28]. In the transactivation 
the EDCs show their estrogenic potency calculated as EC50, respect to the positive 
control, 17β-estradiol. Indeed, a water environmental contaminant such a mixture 
of 4n-nonylphenol showed a significant activation of ER in both transfected firefly 
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luciferase reporter cell, MCF-7 and HeLa cell [28]. Another transactivation assay 
using MELN cells (derived from MCF-7) stable transfected with the estrogen 
responsive gene ERE-βGlob-Luc-SVNeo, showed robustness and reproducibility 
in the screening of estrogenic potency of a panel of chemicals selected from a 
European project ReProTect. In this study test compounds ranked from highest to 
lowest of estrogenic potency, then 17α-ethynylestradiol > 17β-estradiol > hexestrol 
> diethylstilbestrol > norethynodrel > nonylphenol > n-butylparaben in the range of 
10-12-10-10 M; three chemicals showed a moderate ER activation with a ranking as 
follow: genistein > equol > o,p_-DDT having EC50-values in a very narrow range 
from 0.99×10−6 to 3.35×10−6 M [29]. However, the in vitro assays have not the 
same sensitivity to detect estrogenic potency. Indeed, Gutendorf and Westendorf 
reported a decrease of EC50 value for 17β-estradiol into different cell assays as 
follows: MVLN-cells=E-Screen > HGELN-cells (HGELN cells (derived from 
HeLa cells) > binding to ER- α binding to ER β. While a good correlation was 
registered for the other tested chemicals such as Bisphenol A but not for genistein 
which its relative potency ranked in the range of 10−4–10−5 M [24]. 
In vivo evidence of estrogenic like behaviour of EDCs has been investigated in 
animal models (mammalian and other species). Nowadays the use of the classical 
toxicological strategy is limited to the case when there is not a strong evidence from 
existing data of the scientific literature or from the in silico and in vitro testing based 
on OECD, ECHA, EFSA requirements, to reduce the number of laboratory animals 
as well as to follow the 3R principles, replacement, reduction and refinement. [30]. 
The reported Table 1, level 3 above shows the state of science to determine the 
biological effects in vivo. 
Several works in the literature made a correlation between in vitro and in vivo 
experiments. Sonneveld et al, established a good correlation between the in vitro 
test ERα-CALUX and the in vivo ovariectomized test in young rats by scoring 
vaginal cornification (Allen-Doisy test) [31]. Nevertheless, the plausibility of the 
in vivo model are still some limitations such as a lack of certainty on the suitability 
of animal species treated and its life stages, a lack of correlation between the 
mechanistic of actions (which are predictive of the endocrine disrupting concern) 
and the apical response observed in vivo, i.e. the adverse outcomes [32]. In the last 
period new in vivo approach based on transgenic mouse model have been generated 
 17 
 
to measure estrogen receptor (ER) transcriptional activity in living organisms [33] 
(further detail in the vivo paragraph of this thesis). 
 
 
 
 
1.8 Chemicals of interest 
 
I focused on few compounds of industrial and regulatory relevance such as:  
 
 
4,4'-isopropylidenediphenol, Bisphenol A, (BPA) 
(CAS No. 85-05-7) is a synthetic chemical widely 
produced and used in the manufacturing of 
polycarbonate plastics and epoxy resins. This substance is manufactured and/or 
imported in the European Economic Area in 1000000 - 10000000 tons per year 
[34]. This substance has a broadly application in the production of consumer 
products such plastic food containers (e.g. bottles, baby bottles, dishes), food 
packaging (canned food), thermal paper, articles made of PVC, also toys and 
medical equipment’s contain BPA, and others consumer and professional use.  
Migration from those products represents the major routes of human exposure even 
if there are accountable environmental sources such as surface water (during 
swimming) and outdoor air (inhalation of aerosols). In addition, the release of BPA 
from epoxy-based floorings, adhesives, paints, electronic equipment and printed 
circuit boards is reported to be a source of contamination of indoor air (including 
airborne dust) and dust [35]. Indeed it was estimated different BPA concentration 
if food matrices as consequence of a migration process, e.g. in some canned food 
categories have an average (MB) BPA concentration above 30 μg/kg, such as grain 
and grain-based products, legumes, nuts and oilseeds, meat and meat products, fish 
and other seafood; other canned food categories have average BPA concentrations 
(MB) between 2.7 and 23.5 μg/kg, such as vegetables and vegetable products, fruit 
and fruit products, fruit and vegetable juices, milk and dairy products. While from 
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the environmental sources, e.g. at the urban traffic site, the BPA concentrations in 
the particulate phase ranged from 0.06 to 18.6 ng/m3 (average 6.78 ng/m3); at the 
industrial site the BPA concentrations ranged from LOD to 47.3 ng/m3 (average 
13.2 ng/m3). 
The estimated BPA dietary intake was highest in infants and toddlers, up to 0.875 
µg/kg body way (bw) for day. Women of childbearing age had dietary exposures 
comparable to men of the same age (up to 0.388 µg/kg bw day). The highest 
aggregated exposure of 1.449 µg/kg bw day was estimated for adolescents [35]. 
BPA has raised concern for its high production volume and for the evidence of 
toxicity in laboratory animal studies mainly on reproductive and developmental 
systems, liver, kidney some evidence of alteration and cancer in the mammary 
gland [16,36-39]. So according to the strong evidence of animal toxicity, ECHA 
has classified the BPA as toxic for reproduction category 1B (according to art. 57 
of Regulation (EC) No 1272/2008 on the classification, labelling and packaging of 
substances and mixtures (CLP Regulation) [34]. Although on 2015 EFSA has 
issued a scientific opinion that BPA does not pose no health risk to all consumers 
(including infant and pregnant women) because the current exposure to the 
chemical is too low to cause harm. In addiction EFSA has established a temporary 
TDI (tolerable daily intake) of 4 micrograms per kilogram of body weight per day 
based on the toxicological effect on mean relative kidney weight in a mouse study 
[35]. 
 
 
3,4-Bis(4-hydroxyphenyl)-hex-3-ene or 
Diethylstilbestrol, DES, (CAS No. 56-53-1) is a 
synthetic nonsteroidal estrogen. It was widely 
prescribed in the United States from the early 1940s 
until 1971, primarily as a treatment to prevent miscarriages or premature deliveries, 
control of menstrual disorders, relief or prevention of postpartum breast engorge-
ment, palliative therapy for cancer of the prostate in men and breast cancer in 
postmenopausal women, and as a post-coital contraceptive. Diethylstilbestrol has 
also been used in veterinary medicine and as a growth promoter (as a feed 
supplement or subcutaneous implant) in cattle, sheep, and poultry (IARC 1979). Its 
use as a growth promoter was banned in 1979. Its use as human therapy was stopped 
 19 
 
for the first time in the 1978 when the U.S. Food and Drug Administration (FDA) 
withdrawn the approval of any estrogen-containing drug product (including 
diethylstilbestrol). Then this substance went under evaluation the International 
Agency for Research on Cancer (IARC) that in the 1978 and 1987 confirmed that 
diethylstilbestrol was a human carcinogen (category 1A) based on sufficient 
evidence of carcinogenicity from studies in humans. The evidence of 
carcinogenicity in human has been discovered from epidemiological studies of 
1970 where it was determined the association of women exposed to 
diethylstilbestrol in utero (“diethylstilbestrol daughters”), to clear-cell 
adenocarcinoma of the vagina or cervix. While in another cohort study it has been 
reported an increased risk of testicular cancer among diethylstilbestrol sons. Also, 
the evidence of carcinogenicity has been demonstrated in experimental animals by 
several routes of administration (e.g. oral, subcutaneous implantation). Prenatal 
exposure to diethylstilbestrol caused benign cervical and vaginal tumours 
(epidermoid tumours) in female mice, benign and malignant cervical and vaginal 
tumours (polyps, squamous-cell papilloma, and myosarcoma) in female hamsters, 
and benign and malignant testicular tumours (granuloma, adenoma, and 
leiomyosarcoma) in male hamsters. Also, in adult animal study DES caused 
carcinogenicity [15; 16; 40]. 
 
17β-estradiol (CAS No: 50-28-2) is a potent 
mammalian estrogenic hormone; it is produced in the 
ovary, placenta, testis, adrenal cortex. It is also 
produced by the adipose tissue of men and 
postmenopausal women. Estradiol has been used in estrogenic hormone therapy for 
the treatment of menopausal and postmenopausal symptoms, metastatic prostate 
cancer, & breast cancer [41]. Because of its natural affinity and potency to Estrogen 
receptors [10] 17β-estradiol has been using as positive reference compound in 
toxicological studies such as in the reproductive and developmental testing or in the 
mechanistic studies [13; 31; 42; 43] and pharmacological research [11]. Estradiol 
is to be considered as a carcinogenic chemical in woman in post-menopausal 
estrogen therapy. There is a strong evidence of carcinogenicity in several organs in 
animal studies. Mammary, pituitary, uterine, cervical, vaginal, testicular, lymphoid 
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and bone tumours were observed in mice. Also, β-estradiol induced mammary and/ 
or pituitary tumours in rats. In hamsters and in guinea pigs malignant kidney 
tumours were noted. It was also reported the evidence of genotoxicity of 17β-
estradiol [44]. 
 
Di-2-ethylhexyl phthalate, DEHP, (CAS No: 
117-81-7) is a high production volume chemical 
used as a plasticizer of polyvinyl chloride in the 
manufacture of a wide variety of consumer 
goods, such as building products, car products, clothing, food packaging, children’s 
products, and in medical devices made of polyvinyl chloride [45]. Because of its 
widespread use, it also represents a widely environmental pollutant. DEHP is 
expected to be strongly adsorbed to organic matter. DEHP is therefore expected to 
be found in the solid organic phase in the environment. DEHP has the property to 
bioaccumulate in aquatic organisms [46]. Human can be subjected to combined 
routes of exposure such as ingestion, inhalation and dermal exposure. It is estimated 
that the general population of the United States is exposed to DEHP levels ranging 
from 1 to 30 μg/kg bw day) [45]. Concentrations of DEHP and its metabolites 
detected at levels above the LOD have been characterized in urine samples from of 
mothers and their sons [47]. DEHP has been raising concern for its predominantly 
anti-androgenic activity elicited both in vitro and in vivo studies. While it is 
considered a weaker estrogenic compound [48]. In vitro DEHP caused cytotoxicity 
to MVNL cells line and displayed weak estrogenic potency in the MVLN 
transactivation assays. it decreased testosterone concentration in the H295R 
Steroidogenesis assay [49]. In a reproductive study (in utero and lactational 
exposure), it was reported a reduced daily sperm production and sperm quality and 
tract abnormalities (e.g., cryptorchidism) in adult male offspring. In this study the 
authors established a lowest observed adverse effect levels (LOAELs) for these 
effects were 15 and 5 mg/kg/day, respectively. Therefore, the no observed adverse 
effect level (NOAEL) for this study was set at 1.215 mg/kg/day [50]. 
The EFSA Scientific Panel on Food Additives, Flavourings, Processing Aids and 
Materials in Contact with Food (AFC) in 2005 determined a TDI of 0.05 mg/kg bw 
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day, based on the NOAEL of 5 mg/kg bw day for testicular toxicity observed in a 
feed multigeneration reproductive assessment in rats [51]. 
 
Methoxychlor (CAS No. 72-43-5) is a synthetic 
organochlorine insecticide used in the crop 
protection of ornamentals, livestock against a wide 
range of insects that attack fruits, vegetables, shade trees, home gardens, forage 
crops, and livestock. It is also used for the spray treatment of barns, grain storage 
bins, mushroom houses, dairies [52]. So, the agriculture activities, food and water 
contamination represented the mainly route of exposure to famers or people living 
close to area where methoxychlor was used. 
The toxicity of methoxychlor was clear in the animal rather than human. Exposure 
to high concentrations of methoxychlor caused adverse effects to the animal 
nervous system. Some breakdown products of methoxychlor produced adverse 
effects similar to those produced by estrogen such as alteration in ovaries, uterus, 
and mating cycle in females, and the testes and prostate in males. Also, infertility 
occurred in both female and male animals. Those effects were seen both in adult 
animals and in developing animals exposed prenatally or shortly after birth [53]. In 
another study methoxychlor caused a decrease of weight of testis, prostate, seminal 
vesicles in adult rats feed at 50 and 100mg/kg bw day [54]. 
 
  
4-nonylphenol (CAS No. 104-40-5) is an 
environmental pollutant arising from the 
degradation of non-ionic surfactants in 
sewage, Nonoxynol-9, one of the APEs (alkylphenol polyethoxylates), used as a 
surfactant in cleaning, in cosmetic products, as a spermicide in contraceptives. 
Nonylphenol is an organic compound which belongs to the wide family of 
alkylphenols. It is a product of industrial synthesis formed during the alkylation 
process of phenols, particularly in the synthesis of polyethoxylate detergents. 
Because of their man-made origins, nonylphenols are classified as xenobiotics [55]. 
This alkylphenol raised concern for its ability to affect the reproductive organs in 
female and male laboratory animals. Most alkylphenols showed an affinity to the 
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estrogen receptors in a concentration-dependent manner and thus potentially act as 
activators (agonists) or inhibitors (antagonists) of cellular responses mediated 
through the estrogen receptor. The binding activity of alkylphenols is associated 
with the presence of substituted alkyl group [56]. Law and co-workers found it out 
the 4-nonylphenol induced a significant increase in uterine weight in the prepubertal 
rats after oral administration. Also, the age of vaginal opening was advanced 
following oral exposure from postnatal days 21–35 [57].  
 
 
Vinclozolin (CAS No. 50471-44-8) was previously used 
as a fungicide on some fruits, nuts, vines, vegetables, 
ornamentals and wood preservative in the US. After 2004, 
its use in the US was restricted to only include use on 
canola and on turf used on golf courses and industrial 
sites. The only food import allowed following use of vinclozolin is wine grapes. 
Some other countries continue to use this fungicide [58]. Human data are very 
limited. It has low toxicity following single exposures via the oral, inhalation, or 
dermal route. The most sensitive targets to the toxicity of vinclozolin are the male 
reproductive organs. At low dose levels (>3 mg/kg/day), vinclozolin produced a 
decrease of prostate weight, reduction of nipple/areolas development, and decrease 
of ano-genital distance in male rats. At higher dose levels, the reduction of weight 
of male sexes organs is exacerbated, and sex organ malformations are seen, such as 
reduced penis size, ectopic testes, vaginal pouches, hypospadias, and additional 
ambiguities of the urogenital system [59]. This anti-androgenic activity is due to 
the binding to androgen receptor (AR) [60] or to other receptors such as the 
progesterone (PR), glucocorticoid (GR), mineralocorticoid (MR) or estrogen 
receptors (ERα and ERβ) [61]. 
 
 
Zearalenone (CAS No. 17924-92-4) is a 
phenolic resorcyclic acid lactone mycotoxin 
produced by several Fusarium species. It is 
commonly found in maize, but it can be found also in other crops such as wheat, 
barley, sorghum and rye. People are exposed mainly through the diet based on the 
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consumption of a breakfast cereal. It is estimated a chronic dietary exposure in the 
range concentration from 2.4 ng/kg bw day to 54 ng/kg bw for high consumers. 
Infant and toddler are the most exposed consumer. 
EFSA Contam Panel has derived a TDI of 0.25 μg/kg bw day based on the NOEL 
(no observed effect level) of 10 μg/kg bw. per day derived from a reproductive and 
development toxicity study in immature female pigs, considered as the most 
sensitive species to the estrogenic action of the zearalenone and its metabolites such 
as α-zearalenol. The estrogenic effects associate to this mycotoxin were the 
alterations of the oestrous cycle, ovulation, conception and implantation, embryonic 
death, reduced fetal weight, reduced litter size and impaired neonatal survival. 
The toxicity of the zearalenone was considered relevant for the human health 
because the reproductive tract of female pigs was like the woman ones [62]. After 
the ingestion, zearalenone is metabolized to a secondary product with a higher 
estrogenic activity than the parent compound, by the CYP450 or other enzymes as 
3α- and 3β-hydroxysteroid dehydrogenases (HSDs) family. Among these 
metabolites, α-zearalenol was linked to an alteration of steroidogenesis production 
as the parent compound does, in Leydig cells of mice [63] and in the H295R 
steroidogenesis assay where increased the production of progesterone, estradiol, 
testosterone and cortisol hormones [65]. Oral administration of zearalenone to adult 
male mice produced only adverse effects on the sperm parameters such as the 
decrease of sperm concentration and the increase of morphologically abnormal 
spermatozoa [65]. In the subchronic and chronic toxicity studies of NTP (technical 
report 235, 1982) [66] zearalenone caused atrophy of testis and seminal vesicles in 
both male rats F344/N and mice B6C3F1. These effects were observed also in the 
90 days toxicity studies in rats at 27 – 270 mg/kg bw per day while in the 104 weeks 
toxicity study only the testes were sensitive to low doses (1.25-2.5 mg/kg per day). 
In the subchronic and carcinogenicity studies, male mice B6C3F1 treated at 
different doses, 9 and 150 and 450 mg/kg bw per day, developed a testicular 
atrophy. In NTP studies also the prostate was altered. Indeed, the rats developed a 
hyperplasia at 27 mg/kg bw per day in the subchronic study, while in 
carcinogenicity study was observed an increase of inflammation at both doses tested 
(1 and 2 mg/kg bw per day). In mice there was an incidence of squamous metaplasia 
at 450 mg/kg bw per day in the 13 weeks exposure study, while no adverse effect 
was detected in the carcinogenicity test. 
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Zearalenone was also defined as ER agonist [13]; it was determined a high value of 
half maximal inhibitory concentration (IC50) in estrogen receptor competitive 
binding assay [67], while different transactivation assays (as in Hela cells) 
determined that zearalenone was a potent activator of estrogen receptor [68; 69]. 
 
 
Genistein, is an isoflavone that occurs in soy 
products. Human exposure to genistein comes is 
predominantly through the consumption of soy 
products, including soy-based infant formula and 
dietary supplements. The consumption of soy and thus of genistein, has been 
associated with a variety of beneficial effects in animals and humans. Nevertheless, 
some concerns have also been raised regarding the putative toxicity of genistein, 
particularly regarding on the reproductive system or the induction or potentiation 
of carcinogenesis, due to its weak estrogenic activity [70]. Indeed, in in vitro ER 
binding assay genistein showed a lower relative binding affinity towards ERα as 
reported by Kuiper [10] and by Gutendorf et al. [24]. 
In addition, the estrogenic potency of genistein was assessed to be several orders of 
magnitude lower than 17β-estradiol one in different in vitro assays [24]. In the 
animal testing, this isoflavone was linked to an alteration of both female and male 
reproductive organs. In a subchronic study where adult female rats were exposed to 
high concentration (500 mg/kg bw per day) of genistein, was observed an increase 
of ovarian and uterine weights, while in a carcinogenicity assay there was an 
increase of metaplasia and squamous metaplasia of uterine cervix, increase of 
uterine weight, uterine horn dilation at the same dose [71]. Also, male species were 
affected by the exposure to genistein mainly during the most sensible window as in 
utero exposure. In the multigenerational study done by NTP the male rats exposed 
during all pregnancy till to the adult age had significant increased weight of prostate 
[72].  
However, even there is some evidence of toxicity of genistein from animal studies, 
maybe through the ER activation, EFSA opinion stated the safety of isoflavone 
consumption from soy-products [73]. 
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1.9 Aim 
 
The general aim of the project was to develop an integrated strategy of testing based 
on the combination of scientific literature review of in vivo data, in silico method, 
cellular and animal bioluminescence imaging methodologies to predict among a set 
of chemicals those with an endocrine disrupting activity or ability to activate other 
toxicological pathways such as inflammation and oxidative stress measured in the 
male reproductive organs and in the genital and abdominal area of mice. The 
selected molecules range from known (DES), to suspected (BPA), endocrine 
disruptors and included both synthetic (DEHP) and natural (genistein) compounds. 
Therefore, the assessment of ED activity/mechanism and the activation of 
inflammatory and oxidative stress pathways (as indirect toxicological mechanisms) 
of selected chemicals is based on the final observation of the correlation between 
the computed binding affinity values (binding free energies of chemicals towards 
human estrogen receptor, see Material and Methods), the following determinations 
of the dynamic ER activations quantified by in vitro and in vivo bioluminescence 
imaging methodologies and the available toxicological information from the 
literature.  
The in vitro testing is a ERE-Luc reporter system where that is the cell transfection 
assay in ERE-Luc B17 cells, a clone of the breast cancer cell line MCF-7 stably 
transfected with a luciferase reporter system of estrogenic activity. The in vivo 
imaging was conducted in 3 different male transgenic mice carrying a firefly 
luciferase reporter system: one type under the control of estrogen-responsive 
promoter (ERE-Luc), ones under the control of inflammation pathway (NFkB-
Luc), and the last was responsive to oxidative stress signaling (ARE-Luc).  
Because of the nature of endocrine disruptors to alter the reproductive tract we have 
restricted our investigation on the ability of specific compound to activate the 
luciferase systems (ERE-Luc, NFkB-Luc and ARE-Luc) in the genital area of the 
transgenic mice. The abdominal area and intestine were integrated into the analysis 
as controls because of the high expression of the estrogen receptor.  
The activities have been scheduled as reported below: 
 
 
 26 
 
1° 
year 
Literature search to retrieve toxicological data inherent to the 
reproductive alterations of our selected set of chemicals. 
Application of in silico model to human ERα to prioritize the chemicals 
based on their different ability to bind the receptor 
2° 
year 
Gathering of information on available in vitro systems that elucidate the 
mechanism of action of estrogen like compound. Then focus on reporter 
cells system such as that used in this project activity ERE-Luc B17 cells, 
a clone of the breast cancer cell line MCF-7. Imaging of ER activity in 
the reporter ERE-Luc cell to measure the EC50 of the compounds to be 
prioritized for the in vivo assay. 
3° 
year 
In vivo imaging of ER activity in reporter mice of compounds which 
were prioritized in the in vitro assay. Integration of all results in a 
rationale flow to be use in the toxicological risk assessment.  
 
 
 
 
Chapter 2 
 
2.1 Materials and Methods 
 
2.2 Chemicals used in the luciferase reporter systems 
 
Reagents: 17β-estradiol (CAS Number 50-28-2, purity 100%), Diethylstilbestrol 
(CAS Number 56-53-1, purity≥ 99%), Zearalenone (CAS Number 17924-92-4, 
purity ≥ 99%, stored condition at -20 °C), Bisphenol A (CAS Number 80-05-7, 
purity ≥ 99%), Genistein (CAS Number 446-72-0, purity ≥ 98%), Methoxychlor 
(CAS Number 72-43-5, purity ≤ 100%), Vinclozolin (CAS Number 50471-44-8, 
purity ≤ 100%), Bis(2-ethylhexyl) phthalate (CAS Number 117-81-7, purity ≤ 
100%), 4-nonylphenol (CAS Number 104-40-5, purity ≤ 100%), Dimethyl 
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sulfoxide DMSO (CAS Number 67-68-5), were purchased form Sigma Aldrich 
S.r.l. The cell culture media RMPI 1640 supplemented was from LIFE 
Technologies Europe BV. 
 
2.3 Literature search of endocrine disruptor endpoints 
 
 The existing toxicological data on the substances tested in the project, where 
collected from available research works where the apical effects on endocrine 
system ware investigated after oral (diet > drinking water > gavage) administration 
of the compounds. Only the toxicological data from rodent species (both sexes of 
mice and rats) were collected, except a study showing adverse effects of 
zearalenone on the reproductive system of female pig. The endpoints of interest 
were based on the ECHA and EFSA “Guidance for the identification of endocrine 
disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 
1107/2009” and on the OECD (Organization for Economic Co-operation and 
Development) framework “Guidance Document 150 on Standardized Test 
Guidelines for Evaluating Chemicals for Endocrine Disruption, revised 2018” [18] 
(Table 1, previously reported). The checked database were first that of National 
Toxicological Programs Database where the studies reports are considered of high 
quality and reliability, then the others were: Toxnet, eChemPortal by the OECD 
which allows simultaneous searching of reports/datasets through the chemical name 
and number, the chemical properties and it also provides a direct link to collections 
of use, exposure, hazard and risk information from government chemical review 
programs at national, regional and international levels; Chembase, ChemIDplus, 
ChemSpider, Carcinogenic Potency Database, DSSTox, European chemical 
Substances Information System, PubChem BioAssay Database that contains 
bioactivity screens of chemical substances described in PubChem Substance. It 
provides searchable descriptions of each bioassay, including descriptions of the 
conditions and readouts specific to that screening procedure. 
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2.4 In silico methodology 
 
All the computational procedures were carried out by the Schrödinger Small-
Molecule Drug Discovery Suite 2018-32. The crystallographic structure of the 
ligand binding domain of human estrogen alpha bound to estradiol was downloaded 
from the RCSB PDB (code: 3UUD, chain A) [74]. The Schrödinger Protein 
Preparation Wizard was used for locating and fixing structural defects or missing 
information in ERα structure and preparing it for use with Schrödinger Glide for 
molecular docking. Tested ligands were built by the Schrödinger Maestro Build 
Toolbar and prepared for docking by the Schrödinger Ligand Preparation. The 
molecular docking procedure was carried out by the Schrödinger Glide Docking in 
“extra precision, XP” mode, which is an estimation of the binding free energy, in 
order to evaluate the ability of the tested ligand to bind the ERα ligand binding 
domain.  
The top-scoring solution for each ligand was submitted to Schrödinger Prime MM-
GBSA, which integrates molecular mechanics energies combined with the 
generalized Born and surface area continuum solvation [75] in order to calculate 
ligand binding and ligand strain energies for a set of ligands and a single receptor. 
The dissociation constant (Ki) was computed starting from empirical binding free 
energy values, according to the following equation: 
 iKRTG ln  
where R represents the gas constant and T the temperature. Ki was computed 
starting from the binding free energy values at a fixed temperature (300 K) 
 
 
2.5 In vitro bioluminescence imaging assay 
 
The ability of the compounds to transcriptionally activate ERα was tested in ERE-
Luc B17 cells, a clone of the breast cancer cell line MCF-7 stably transfected with 
a reporter constituted by the luciferase gene driven by an estrogen-regulated 
synthetic promoter previously generated and tested in laboratory of Professor Ciana 
[76] and already successfully used in other researches [77; 78].  
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Cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) 
(Euroclone, UK), 50 U/mL penicillin G, 50 μg/mL streptomycin sulfate, 2 g/L 
sodium carbonate, and 0.11 g/L sodium pyruvate at 37 °C at 99% humidity and 5% 
CO2. Cells were split twice a week by seeding 2 × 106 cells in 100 mm diameter 
Petri (Corning, MA) dishes. For transactivation studies, 105 cells/well were seeded 
in 96 well plate in phenol red-free RPMI 1640 medium (Sigma-Aldrich, MO) 
supplemented with 10% dextran-coated charcoal stripped FBS, 1% essential amino 
acid, 1% vitamin mixture, 50 U/mL penicillin G, 50 μg/mL streptomycin sulfate, 2 
g/L sodium carbonate, and 0.11 g/L sodium pyruvate and kept at 37 °C in a 
humidified incubator for 24 h.  
Next, culture medium was replaced with RPMI 1640 with 1% stripped FBS, and 
cells were incubated for a minimum of 4 h before adding 17β-estradiol or selected 
EDCs at increasing concentrations (6-10 depending on the in vitro toxicity) of each 
compound. 
After 6h and 48h of incubation the treated cells were rinsed once with PBS before 
preparing the bioluminescence detection by CCD camera in presence of luciferin 
substrate. Then the bioluminescence imaging sessions were carried out on the same 
treated cells after 6h and 48h of treatments. As a control, all compounds were run 
in parallel with 17β-estradiol. The in vitro assay was repeated two times, with three 
replicates at each tested concentration (see Figure 7 as an example). 
With this system the activity of ER following activation can be easily directly 
detected by a bioluminescence imaging simply after adding the substrate luciferin 
to the culture medium of the reporter cells. The ER activations are then quantified 
by the bioluminescence imaging of photon emissions from the treated cells (with 
different concentrations of tested chemicals (in the range of micromolar to 
picomolar) by using a CCD camera, also used in approach routinely applied for in 
vivo imaging experiment [11; 12], which takes a picture of photon emission at 6 
and 48 hours of incubation (Figure 7). 
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2.6 In vivo bioluminescence imaging experiments 
 
In the in vivo bioluminescence imaging, the selected compounds plus a positive 
control and the vehicle were orally administered to three different reporter mice. 
The ERE-Luc mouse model is a transgenic mouse previously generated by prof. 
Ciana [76] to measure the ER activity in the mouse tissues. Briefly, the construct 
used for transgenesis consisted of the reporter gene (firefly luciferase) driven by a 
dimerized ERE and a minimal promoter. Insulator sequences, the matrix attachment 
region from chicken lysozyme, were used to flank the reporter system in the 
transgenesis construct to achieve a generalized, hormone-responsive reporter 
expression [12]. This model was already successfully and routinely used in other 
works, demonstrating that in this animal model luciferase activity is strictly related 
with the state of ER transcriptional activity [11; 12; 33; 79; 80]. 
The insulator technology was successfully applied to the generation of the other 
model of reporter mice used in this step of the project. The transgenic mice were 
transfected with a reporter system for the inflammatory (NFkB-Luc) and oxidative 
stress (ARE-Luc) pathways. 
The in vivo bioluminescence imaging represents a newly non-invasive procedure 
to quantify the interactions of the xenobiotics, in this case estrogen like compounds, 
Figure 7. Example of bioluminescence imaging o of photon emission after 
 treatment with different concentrations (three replicates at each tested 
concentrations) of Bisphenol A at 6h and 48h. 
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with the reporter luciferase constructs expressed in transgenic mouse, by the 
charge-couple device (CCD) camera detection which takes a “picture” of the photon 
emissions arising from the mouse tissues as a consequence of ER activation [11; 
12; 33; 79; 80] or inflammation or oxidative stress pathways stimulations. 
Also, this non-invasive approach allowed us to quantify by bioluminescence 
imaging the biological events (e.g. the activations of mentioned pathways) 
occurring in the same mouse during the entire time of experiment. Thus, the mouse 
has become itself both its “control group” for the quantification of the baseline 
bioluminescence values (background noise) and the “experimental group” during 
the quantifications of the bioluminescence in response to the treatments. So, any 
biological variation observed are normalized on the basic (baseline 
bioluminescence) values of the same individual, reducing the component of 
variability of the measurements among different individuals. 
At least this methodology allows also to reduce the number of experimental groups 
thanks to a limited variability of less than 10% of the standard deviation. Our 
knowledge of the imaging models used in the project on which preliminary 
observations were made allowed us to make a hypothetical estimation of the noise, 
the signal (effect size) and the signal to noise ratio (S / N). Thanks to this estimate, 
we were able to determine the number of animals per experimental group to be used 
in our study based on the following parameters: 
• significance level of 5% 
• power equal to 80% 
• signal / noise ratio of 1.2 
Based on these parameters and referring to what was suggested on the website 
http://www.3rs-reduction.co.uk, we have therefore established the number of our 
samples as N=4 mice for each treatment as also reported in previously works using 
this non-invasive methodology both in male and female transgenic mice [81]. The 
following protocol used in my research describes how to run an in vivo imaging 
experiment: 
4 heterozygous young male mice C57BL/6 were enrolled for each treatment. Before 
the beginning of the experimental study, the baseline luciferase activity was 
measured in all animals by in vivo imaging (D0 or baseline). The anaesthetized 
untreated mice were doped with substrate and the introduced inside the CCD 
camera for 5 minutes to get the baseline luciferase activity. The day after the 
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compounds Bisphenol A (10 and 100 mg/kg/day, BPA10 and BPA100), 
Zearalenone (10 and 150 mg/kg/day, ZEA10 and ZEA150), 17β-estradiol, positive 
control, (10 and 100 μg/kg/day, E10 and E100) and vehicle (2-hydroxypropyl-β-
cyclodextrin) were daily administered by drinking water for 21 days to transgenic 
mice. 
The bioluminescence imaging session was done every morning at 10:00. The 
animals were injected i.p. with 80 mg/kg of luciferin (Beetle Luciferin Potassium 
Salt; Promega, Madison, WI, USA) 15 minutes prior bioluminescence 
quantification, to obtain a uniform biodistribution of the substrate. For the imaging, 
mice were anaesthetized using isoflurane (Isoflurane-Vet; Merial, Lyon, France) 
and kept under anaesthesia during the 5 minutes of the session carried out with a 
CCD camera which took a picture of bioluminescence emissions. Photon emission 
in selected body areas was measured using the Living Image Software (Caliper, 
PerkinElmer company). The analysis was done in ventral view: whole body, head, 
thymus, chest, abdominal, genital area, tail, paw and expressed as 
photon/second/cm2/sr radiant (p/s/cm2/sr). At the end of treatment On day 21, 
terminal study, , the animals were sacrificed by the intraperitoneal injection of lethal 
mixtures (ketamine >280.8 and xylazine >21.6 mg/Kg), then the selected organs 
were excised and placed into the CCD camera for the ex vivo bioluminescence 
imaging procedure in order to directly quantify the photon emissions of our 
pathways of interest (hormonal, inflammation and oxidative stress) from localized 
tissue such as intestine, testis, seminal vesicles and prostate. 
The measurements of photon emissions could be quantitatively analysed from the 
selected and specific body areas are by called regions of interest (ROIs) which can 
be also manually selected. The software of CCD camera takes the image of the 
whole animal body and thus we can modify and select the area, the size of ROI 
(highlighted in red borders) (Figure 8). 
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2.7 Statistical analysis 
 
The in vitro bioluminescence imaging assay was carried out in triplicates at each 
concentration tested (figure 7). The analysis of transactivation data and calculation 
of EC50 values were performed by means of sigmoidal dose-response (variable 
slope) using GraphPad Prism v. 7 software (GraphPad Software Inc.).  
In vivo bioluminescence imaging experiment with reporter mice allowed us to 
quantify by bioluminescence imaging the biological events (e.g. the activations of 
mentioned pathways) occurring in the same mouse during the entire time of 
experiment. Thus, the mouse has become itself both its “control group” for the 
quantification of the baseline bioluminescence values  (background noise) and the 
“experimental group” during the quantifications of the bioluminescence as response 
to the treatments. So, any biological variation observed are normalized on the basic 
(baseline bioluminescence) values of the same individual, reducing the component 
of variability of the measurements among different individuals. 
Figure 8: selection of regions of 
interest (ROI) on the 
bioluminescence image taken by 
CCD camera, for whole body, 
genital area, head, chest, 
abdominal, paw, tail. 
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Imaging allows to reduce the number of experimental groups thanks to a limited 
variability of less than 10% of the standard deviation. Our knowledge of the 
imaging models used in the project on which preliminary observations were made 
allowed us to make a hypothetical estimation of the noise, the signal (effect size) 
and the signal to noise ratio (S / N). Thanks to this estimate, we were able to 
determine the number of animals per experimental group to be used in our study 
based on the following parameters: 
• significance level of 5% 
• power equal to 80% 
• signal / noise ratio of 1.2 
Based on these parameters and referring to what was suggested on the website 
http://www.3rs-reduction.co.uk, we have therefore established the number of our 
samples as N=4 mice for each treatment. 
The analysis of statistical significance was done by Ordinary one-way ANOVA plus 
Bonferroni's multiple comparisons test with p < 0.05 versus control.  
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Chapter 3 
 
3.1 Results 
 
3.2 Literature search of endocrine disruptor endpoints 
 
Before the programming of experimental part of the project, an extensive 
bibliographic analysis of the available toxicological data was carried out. Those 
data related to a possible endocrine disrupting activity of the selected molecules 
described in the paragraph 1.7. The endpoints of interest focused on the parameters 
described in the “Guidance for the identification of endocrine disruptors in the 
context of Regulations (EU) No 528/2012 and (EC) No 1107/2009” based also on 
OECD (Organization for Economic Co-operation and Development) framework 
“Guidance Document 150 on Standardized Test Guidelines for Evaluating 
Chemicals for Endocrine Disruption, revised 2018” [18; 19]. The aim was to obtain 
any information on the active dose ranges and the potency of each molecule with 
the regard to specific effects in organs targets which are representatives of a 
hormonal activity. The analysis was not able to show any particular correlations 
because of many experiments with different protocols, except few cases, using 
different species, strains, sex, treatment duration, doses etc. Then the attention was 
exclusively focused on data obtained from reliable toxicological studies carried out 
by NTP, except few cases. Thus, the data were restricted to the effects observed in 
the male reproductive organs. An extract of these data is reported in the following 
table 2. 
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Table 2. Extract of data from literature: adverse effects of interest for endocrine disrupting activity on testis, 
seminal vesicles, prostate and liver of male rodent species  
 
• Testis 
 
COMPOUND SPECIES STRAINS ROUTE PROTOCOL 
TREATMENT 
(DAYS) 
DOSE  
(mg/kg bw day) 
EFFECT REFERENCE 
17β-estradiol  Rats 
Crl:CD 
BR  
diet Subchronic toxicity 90 
0.003; 0.139 - 
0.173; 0.5 - 0.7; 
3 - 4 
↓ weight, size, 
Degeneration/atrophy, 
seminiferous tubule 
(0.5, 3) 
Biegel et al., 
1998 [42] 
17β-estradiol Rats 
Crl:CD 
BR  
diet 
Extended One-
Generation 
Reproductive 
Toxicity Study 
in utero + 
lactation + 
77 days 
(Post 
weaning - 
77) 
0.004 - 0.005; 
0.225 - 0.273 
↓ weight (0.225) 
Biegel et al., 
1998 [42] 
Zearalenone  Rats  F344/N  diet Subchronic toxicity 90 
0; 2.7; 9; 27; 90; 
270 
↑Atrophy (27; 90; 270) 
NTP tr 235, 
1982 [66]  
Zearalenone  Rats  F344/N  diet Carcinogenicity 728 1.25; 2.5 ↑Atrophy (1.25>2.5) 
NTP tr 235, 
1982 [66] 
Zearalenone Mice  B6C3F1  diet Subchronic toxicity 90 
0; 4.5; 15; 45; 
150; 450 
↑Atrophy (150; 450) 
NTP tr 235, 
1982 [66] 
Zearalenone Mice  B6C3F2 diet Carcinogenicity 728 
m: 7; 14; f: 10; 
20 
↑Atrophy (9> 17) 
NTP tr 235, 
1982 [66] 
Zearalenone Mice  CD1 
drinking 
water 
One-Generation 
Reproduction 
Toxicity Study  
90 (GD1-
PND70, only 
male pups)  
0.000025; 0.025 no effect 
Zatecka et 
al., 2014] 
[65] 
Genistein Rats SD diet 
Extended One-
Generation 
Reproductive 
Toxicity Study 
64 (GD7-
PND49) 
(only pups 
examination
) 
 
0.3; 1.7; 6.4; 16; 
38; 72  
Pregnant dams 
(GD7- 
parturition) 
 
0.6; 3.5; 14; 37; 
84; 167 
  
Lactating dams 
(Pup PND 1 - 
PND 14)  
 
0.6; 3; 11; 29; 69 
; 166  
F1 male ; 
PND21-PND50 
 
0.6; 3; 12; 31; 
73; 166 
F1 female, PND 
21 - PND 50 
no effect  
NTP tr 79, 
2007 [82] 
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Genistein Rats  SD diet 
Multigeneration 
reproductive 
toxicology 
 
F0: From 
PND 42 to 
PND 140 (98 
days) 
 
F1: From 
conception 
to PND 140 
(161 days) 
F2: From 
conception 
to PND 140 
(161 days) 
F3: From 
conception 
to PND 21, 
fed control 
feed from 
PND 21 to 
PND 140 
(161 days 
total; 42 
days on 
dosed feed) 
 
F4: No 
exposure; 
control feed 
from 
conception 
to PND 140 
(161 days 
total; no 
dosed feed) 
 
F5: No 
exposure; 
control feed 
from 
conception 
to PND 21 
(42 days 
total; no 
dosed feed) 
m: 0; 0.03; 7; 35 
f: 0.5; 10; 50 
↑ weight (abs, rel.) 
(F0, 35); ↑ age at 
testicular descent (F3, 
trend to 35) 
NTP tr 539, 
2008 [83] 
Genistein Rats  SD diet Carcinogenicity 
F0: From 
PND 42 until 
F1 weaning 
(77 days) 
F1 (F1C): 
From 
conception 
to 2 years 
(756 days) 
F1 (F1T140): 
From 
conception 
to PND 140 
(161 days), 
then fed 
control diet 
to 2 years 
F3 (F3T21): 
From 
conception 
to PND 21 
pregnant dams: 
0; 0.5; 9; 45; 
lacting dams: 
0.7; 15; 75;  
period prior to 
PND 140; f: 0.4; 
8; 44; 
m: 0.4; 7; 37; 
period between 
PND 140 and the 
end; f: 0.3; 5; 29; 
m: 0.2; 4; 20 
no effect 
NTP tr 545, 
2007 [70] 
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(42 days); 
then fed 
control diet 
to 2 years 
Genistein Rats  
Long 
Evans 
diet 
One-Generation 
Reproduction 
Toxicity Study  
35 (GD1-
PND21) 
Prenatal: 0.1-
0.2; 6.4-9.1; 
Postnatal: 0.2-
0.4; 12-23  
↓ size (PND40, 0.4;23) 
Wisniewski 
et al., 2003 
[84] 
Genistein Rats  SD diet 
Reproductive and 
development 
toxicity 
14 (PND21-
35) 
22; 90 no effect  
Fritz et al., 
2003 [85] 
Genistein Rats Wistar diet Subchronic toxicity 28 0.5; 5; 50; 500  no effect  
Mc Clain et 
al.; 2006 
[71] 
Genistein Rats Wistar diet Subchronic toxicity 90 
5; 50; 500 ↑ rel. weigh (500); 
↑tubular 
degeneration/atrophy 
(500, reversible after 4 
weeks) 
Mc Clain et 
al., 2006 
[71] 
Genistein Rats Wistar diet Chronic toxicity 364 
5; 50; 500 
↑ rel. weigh (500) 
Mc Clain et 
al., 2006 
[71] 
Bisphenol A Rats SD gavage 
Prenatal and 
Chronic toxicity 
In utero + 
PND1-21 (no 
dosing to 
365) 
0; 0.0025; 0.025; 
0.25; 2.5; 27 
no effect  
NTP RR 09; 
sept [86] 
Bisphenol A Rats SD gavage 
Prenatal and 
Chronic toxicity 
In utero + 
PND1-365 
0; 0.0025; 0.025; 
0.25; 2.5; 25 
no effect  
NTP RR 09; 
sept. 2018 
[86] 
Bisphenol A Rats SD gavage 
Prenatal and 
Chronic toxicity 
In utero + 
PND1-21 (no 
dosing to 
730) 
0; 0.0025; 0.025; 
0.25; 2.5; 28 
↑testes polyarteritis 
(2.5) 
NTP RR 09; 
sept. 2018 
[86] 
Bisphenol A Rats SD gavage 
Prenatal and 
Chronic toxicity 
In utero + 
PND1-730 
0; 0.0025; 0.025; 
0.25; 2.5; 26 
no effect  
NTP RR 09; 
sept. 2018 
[86] 
Bisphenol A Rats F344 diet Carcinogenicity 730 50; 100 
↑ interstitial-cell 
tumours (50; 100) 
NTP tr 215, 
1982 [66] 
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Bisphenol A Mice  B6C3F1 diet Carcinogenicity 730 750; 1500 no effect  
NTP tr 215, 
1982 [66] 
Bisphenol A Rats Wistar gavage 
Reproductive and 
development 
toxicity 
GD7-PND22 
(30) 
 0.025; 0.250; 5 no effect  
Christiansen 
et al., 2014 
[87] 
Bisphenol A Rats SD gavage 
One-Generation 
Reproduction 
Toxicity Study  
GD6-PND90  
0.0025; 0.008; 
0.025; 0.08; 
0.26; 0.840; 2.7; 
100; 300 
↓ size (PND90; F1, 
0.26; 300) 
Delclos et 
al., 2016 
[39] 
Bisphenol A Rats SD diet 
Multigenerational  
reproductive 
toxicology 
130 (F0 
through F3) 
0.0007– 0.003; 
0.015– 0.062; 
0.22– 0.73; 4.1–
15.4; 37.6 –
167.2; 
434 –1823  
no effect  
Tyl et al., 
2002 [36] 
Bisphenol A Mice CD-1 diet 
Multigeneratio  
reproductive 
toxicology 
112 
0.003; 0.03; 0.3; 
5; 50; 600 
↑ testes weights (F1; 
F2; 600); ↑ increased 
incidence of 
minimal to mild 
hypoplasia of the 
seminiferous tubule 
(F1; F2; 600) 
Tyl et al., 
2008 [37] 
 
 
• Seminal vesicles 
 
COMPOUND SPECIES STRAINS ROUTE PROTOCOL 
TREATMENT 
(DAYS) 
DOSE 
 (mg/kg bw day) 
EFFECT REFERENCE 
17β-estradiol Rats  SD gavage 
Reproductive and 
development 
toxicity 
38 (GD6-
PND20) 
0.01 ↓weight (0.01) 
Kang et al., 
2002 [88] 
17β-estradiol Rats 
Crl:CD 
BR  
diet Subchronic toxicity 90 
0.003; 0.139 - 
0.173; 0.5 - 0.7; 
3 - 4 
↓weight, ↑ atrophy 
(0.5, 3) 
Biegel et al., 
1998 [42] 
17β-estradiol Rats 
Crl:CD 
BR  
diet 
One-Generation 
Reproduction 
Toxicity Study  
in utero + 
lactation + 
77 days 
(Post 
weaning - 
77) 
0.004 - 0.005; 
0.225 - 0.273 
↓weight (0.225) 
Biegel et al., 
1998 [42] 
Zearalenone  Rats  F344/N  diet Subchronic toxicity 90 
0; 2.7; 9; 27; 90; 
270 
↑Atrophy (9; 27; 90; 
270) 
NTP tr 235, 
1982 [66] 
Zearalenone  Rats  F344/N  diet Carcinogenicity 728 1; 2 no effect 
NTP tr 235, 
1982 [66] 
Zearalenone Mice  B6C3F1  diet Subchronic toxicity 90 
0; 4.5; 15; 45; 
150; 450 
↑Atrophy (150; 450) 
NTP tr 235, 
1982 [66] 
Zearalenone Mice  B6C3F2 diet Carcinogenicity 728 9; 17; f: 10; 20 no effect 
NTP tr 235, 
1982 [66] 
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Zearalenone Mice  CD1 
drinking 
water 
One-Generation 
Reproduction 
Toxicity Study  
90 (GD1-
PND70, only 
male pups)  
0.000025; 0.025 no effect 
Zatecka et 
al., 2014 
[65] 
Genistein Rats SD diet 
One-Generation 
Reproduction 
Toxicity Study  
64 (GD7-
PND49) 
(only pups 
examination
) 
 
0.3;1.7; 6.4; 16; 
38; 72  
Pregnant dams 
(GD7- 
parturition) 
 
0.6; 3.5; 14; 37; 
84; 167 
  
Lactating dams 
(Pup PND 1 - 
PND 14)  
 
0.6; 3; 11; 29; 
69; 166  
F1 male; PND21-
PND50 
no effect 
NTP tr 79, 
2007 [82] 
Genistein Rats  SD diet 
Multigeneration 
reproductive 
toxicology 
 
F0: From 
PND 42 to 
PND 140 (98 
days) 
 
F1: From 
conception 
to PND 140 
(161 days) 
F2: From 
conception 
to PND 140 
(161 days) 
F3: From 
conception 
to PND 21, 
fed control 
feed from 
PND 21 to 
PND 140 
(161 days 
total, 42 
days on 
dosed feed) 
 
F4: No 
exposure; 
control feed 
from 
conception 
to PND 140 
(161 days 
total, no 
dosed feed) 
 
F5: No 
exposure; 
control feed 
from 
conception 
to PND 21 
(42 days 
0; 0.03; 5; 25 f: 
0.5; 10; 50 
no effect 
NTP tr 539, 
2008 [83] 
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total; no 
dosed feed) 
Genistein Rats  SD diet Carcinogenicity 
F0: From 
PND 42 until 
F1 weaning 
(77 days) 
F1 (F1C): 
From 
conception 
to 2 years 
(756 days) 
F1 (F1T140): 
From 
conception 
to PND 140 
(161 days), 
then fed 
control diet 
to 2 years 
F3 (F3T21): 
From 
conception 
to PND 21 
(42 days), 
then fed 
control diet 
to 2 years 
pregnant dams: 
0; 0.5; 9; 45; 
lacting dams: 
0.7; 15; 75; 
period prior to 
PND 140: 0.4; 7; 
37; period 
between PND 
140 and the end: 
0.2; 4; 20 
no effect 
NTP tr 545, 
2007 [70] 
Genistein Rats  
Long 
Evans 
diet 
One-Generation 
Reproduction 
Toxicity Study  
35 (GD1-
PND21) 
Prenatal: 0.1-
0.2; 6.4-9.1; 
Postnatal: 0.2-
0.4; 12-23  
no effect 
Wisniewski 
et al., 2003 
[84] 
Genistein Rats Wistar diet Subchronic toxicity 28 0.5; 5; 50; 500  ↓size (500) 
Mc Clain et 
al., 2006 
[71] 
Genistein Rats Wistar diet Subchronic toxicity 90 
5; 50; 500 
congestion, ↓ colloide 
(500) 
Mc Clain et 
al., 2006 
[71] 
Genistein Rats Wistar diet Chronic toxicity 182 - 364 5; 50; 500 no effect 
Mc Clain et 
al., 2006 
[71] 
Bisphenol A Rats SD gavage 
Perinatal and 
Chronic toxicity 
In utero + 
PND1-21 (no 
dosing to 
365) 
0; 0.0025; 0.025; 
0.25; 2.5; 25 
no effect 
NTP RR 09; 
sept. 2018 
[86] 
Bisphenol A Rats SD gavage 
Perinatal and 
Chronic toxicity 
In utero + 
PND1-365 
0; 0.0025; 0.025; 
0.25; 2.5; 25 
no effect 
NTP RR 09; 
sept. 2018 
[86] 
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Bisphenol A Rats SD gavage 
Perinatal and 
Chronic toxicity 
In utero + 
PND1-21 (no 
dosing to 
730) 
0; 0.0025; 0.025; 
0.25; 2.5; 25 
no effect 
NTP RR 09; 
sept. 2018 
[86] 
Bisphenol A Rats SD gavage 
Perinatal and 
Chronic toxicity 
In utero + 
PND1-730 
0; 0.0025; 0.025; 
0.25; 2.5; 25 
no effect  
NTP RR 09; 
sept. 2018 
[86] 
Bisphenol A Rats F344 diet Carcinogenicity 730 50; 100 no effect 
NTP tr 215, 
1982 [66] 
Bisphenol A Mice B6C3F1 diet Carcinogenicity 730 750; 1500 no effect 
NTP tr 215, 
1982 [66] 
Bisphenol A Rats Wistar gavage 
Reproductive and 
development 
toxicity 
GD7-PND22 
(30) 
 0.025; 0.250; 5 no effect 
Christiansen 
et al., 2014 
[87] 
Bisphenol A Rats SD gavage 
One-Generation 
Reproduction 
Toxicity Study  
GD6-PND90  
0.0025; 0.008; 
0.025; 0.08; 
0.26; 0.840; 2.7; 
100; 300 
no effect 
Delclos et 
al., 2016 
[39] 
 
 
 
• Prostate 
 
COMPOUND SPECIES STRAINS ROUTE PROTOCOL 
TREATMENT 
(DAYS) 
DOSE 
 (mg/kg bw day) 
EFFECT REFERENCE 
17β-estradiol Rats  SD gavage 
Reproductive and 
development 
toxicity 
38 (GD6-
PND20) 
0.01 no effect  
Kang et al., 
2002 [88] 
17β-estradiol Rats 
Crl:CD 
BR  
diet Subchronic toxicity 90 
0.003; 0.139 - 
0.173; 0.5 - 0.7; 
3 - 4 
↓weight, ↑ atrophy 
(0.5, 3) 
Biegel et al., 
1998 [42] 
17β-estradiol Rats 
Crl:CD 
BR  
diet 
One-Generation 
Reproduction 
Toxicity Study  
in utero + 
lactation + 
77 days 
(Post 
weaning - 
77) 
0.004 - 0.005; 
0.225 - 0.273 
↓weight (0.225) 
Biegel et al., 
1998 [42] 
Zearalenone  Rats  F344/N  diet Subchronic toxicity 90 
0; 2.7; 9; 27; 90; 
270 
↑ Hyperplasia (27; 90; 
270)  
NTP tr 235, 
1982 [66] 
Zearalenone  Rats  F344/N  diet Carcinogenicity 728 1; 2 ↑ inflammation (1;2)  
NTP tr 235, 
1982 [66] 
Zearalenone Mice B6C3F1  diet Subchronic toxicity 90 
0; 4.5; 15; 45; 
150; 450 
↑ squamous 
metaplasia (450>150)  
NTP tr 235, 
1982 [66] 
Zearalenone mice B6C3F2 diet Carcinogenicity 728 
m: 9; 17; f: 10; 
20 
no effect  
NTP tr 235, 
1982 [66] 
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Zearalenone mice CD1 
drinking 
water 
One-Generation 
Reproduction 
Toxicity Study  
90 (GD1-
PND70, only 
male pups)  
0.000025; 0.025 no effect 
Zatecka et 
al., 2014 
[65] 
Genistein Rats SD diet 
One-Generation 
Reproduction 
Toxicity Study  
64 (GD7-
PND49) 
(only pups 
examination
) 
 
0.3; 1.7; 6.4; 16; 
38; 72  
Pregnant dams 
(GD7- 
parturition) 
 
0.6; 3.5; 14; 37; 
84; 167 
  
Lactating dams 
(Pup PND 1 - 
PND 14)  
 
0.6; 3; 11; 29; 
69; 166  
F1 male; PND21-
PND50 
↓ ventral prostate 
weight (F1; 166); ↑ 
Dorsolateral Prostate 
Gland Inflammation 
Ventral Depletion of 
Secretory Fluids (F1; 
166) 
NTP tr 79, 
2007 [82] 
Genistein Rats  SD diet 
Multigeneration 
reproductive 
toxicology 
 
F0: From 
PND 42 to 
PND 140 (98 
days) 
 
F1: From 
conception 
to PND 140 
(161 days) 
F2: From 
conception 
to PND 140 
(161 days) 
F3: From 
conception 
to PND 21, 
fed control 
feed from 
PND 21 to 
PND 140 
(161 days 
total, 42 
days on 
dosed feed) 
 
F4: No 
exposure; 
control feed 
from 
conception 
to PND 140 
(161 days 
total, no 
dosed feed) 
 
F5: No 
exposure; 
control feed 
from 
conception 
to PND 21 
(42 days 
m: 0; 0.03; 5; 25  no effect  
NTP tr 539, 
2008 [83] 
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total, no 
dosed feed) 
Genistein Rats  SD diet Carcinogenicity 
F0: From 
PND 42 until 
F1 weaning 
(77 days) 
F1 (F1C): 
From 
conception 
to 2 years 
(756 days) 
F1 (F1T140): 
From 
conception 
to PND 140 
(161 days), 
then fed 
control diet 
to 2 years 
F3 (F3T21): 
From 
conception 
to PND 21 
(42 days), 
then fed 
control diet 
to 2 years 
pregnant dams: 
0; 0.5; 9; 45; 
lacting dams: 
0.7; 15; 75; 
period prior to 
PND 140: 0.4; 7; 
37; period 
between PND 
140 and the end: 
0.2; 4; 20 
↑ lateral- dorsal 
prostate gland weight 
(F1C; 20 - 37) 
NTP tr 545, 
2007 [70] 
 
Genistein Rats  
Long 
Evans 
diet 
One-Generation 
Reproduction 
Toxicity Study  
35 (GD1-
PND21) 
Prenatal: 0.1-
0.2; 6.4-9.1; 
Postnatal: 0.2-
0.4; 12-23  
↓ size (PND70, 23) 
Wisniewski 
et al., 2003 
[84] 
Genistein Rats  SD gavage 
Reproductive and 
development 
toxicity 
5 (PND1-5) 12.5; 25; 50; 100 no effect  
Nagao et al., 
2001 [89] 
Genistein Rats Wistar diet Subchronic toxicity 28 
0.5; 5; 50; 500  
no effect  
Mc Clain et 
al., 2006 
[71] 
Genistein Rats Wistar diet Subchronic toxicity 90 
5; 50; 500  
↑ inflammation (500) 
Mc Clain et 
al., 2006 
[71] 
Genistein Rats Wistar diet Chronic toxicity 182 - 364 5; 50; 500 
↑ weight (500); ↑ 
inflammation (50; 500) 
Mc Clain et 
al., 2006 
[71] 
Bisphenol A Rats SD gavage 
Perinatal and 
Chronic toxicity 
In utero + 
PND1-21 (no 
dosing to 
365) 
0; 0.0025; 0.025; 
0.25; 2.5; 27 
no effect  
NTP RR 09; 
sept. 2018 
[86] 
Bisphenol A Rats SD gavage 
Perinatal and 
Chronic toxicity 
In utero + 
PND1-365 
0; 0.0025; 0.025; 
0.25; 2.5; 25 
↑dorsal/lateral 
prostate lobes 
inflammation (0.0025) 
NTP RR 09; 
sept. 2018 
[86] 
Bisphenol A Rats SD gavage 
Perinatal and 
Chronic toxicity 
In utero + 
PND1-21 (no 
dosing to 
730) 
0; 0.0025; 0.025; 
0.25; 2.5; 25 
↑ventral 
prostate lobes 
adenocarcinoma 
(0.025) 
NTP RR 09; 
sept. 2018 
[86] 
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Bisphenol A Rats SD gavage 
Perinatal and 
Chronic toxicity 
In utero + 
PND1-730 
0; 0.0025; 0.025; 
0.25; 2.5; 25 
↑dorsal/lateral 
prostate lobes 
inflammation (0.0025); 
ventral lobe prostate 
epithelium hyperplasia 
(0.25); ↑ventral 
prostate lobes 
adenoma (25) 
NTP RR 09; 
sept. 2018 
[86] 
Bisphenol A Rats F344 diet Carcinogenicity 730 50; 100 no effect  
NTP tr 215, 
1982 [66] 
Bisphenol A Mice  B6C3F1 diet Carcinogenicity 730 750; 1500 no effect  
NTP tr 215, 
1982 [66] 
Bisphenol A Rats Wistar gavage 
Reproductive and 
development 
toxicity 
GD7-PND22 
(30) 
 0.025; 0.250; 5 no effect  
Christiansen 
et al., 2014 
[87] 
Bisphenol A Rats SD gavage 
One-Generation 
Reproduction 
Toxicity Study  
GD6-PND90  
0.0025; 0.008; 
0.025; 0.08; 
0.26; 0.840; 2.7; 
100; 300 
no effect  
Delclos et 
al., 2016 
[39] 
Bisphenol A Rats SD diet 
Multigeneration 
reproductive 
toxicology 
130 (F0 
through F3) 
0.0007– 0.003; 
0.015– 0.062; 
0.22– 0.73; 4.1–
15.4; 37.6 –
167.2; 
434 –1823  
↓weight (434) 
Tyl et al., 
2002 [36] 
Bisphenol A Mice CD-1 diet 
Multigeneration 
reproductive 
toxicology 
112 
0.003; 0.03; 0.3; 
5; 50; 600 
no effect  
Tyl et al., 
2008 [37] 
 
 
• Liver  
 
COMPOUND SPECIES STRAINS ROUTE PROTOCOL 
TREATMENT 
(DAYS) 
DOSE 
 (mg/kg bw day) 
EFFECT REFERENCE 
17β-estradiol Rats 
Crl:CD 
BR  
diet Subchronic toxicity 90 
0.003; 0.139 - 
0.173; 0.5 - 0.7; 
3 - 4 
↑ relative weight; ↑ 
slight to mild 
centrilobular 
hepatocellular 
hypertrophy (F0, ♂, 
0.5) 
Biegel et al., 
1998 [42] 
Zearalenone  Rats  F344/N  diet Subchronic toxicity 90 
0; 2.7; 9; 27; 90; 
270 
no effect 
NTP tr 235, 
1982 [66] 
Zearalenone  Rats  F344/N  diet Carcinogenicity 728 1.25; 2.5 
↑ Cytoplasmic 
vacuolization (♂, 1.25; 
2.5) 
NTP tr 235, 
1982 [66] 
Zearalenone mice B6C3F1  diet Subchronic toxicity 90 
0; 4.5; 15; 45; 
150; 450 
no effect 
NTP tr 235, 
1982 [66] 
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Genistein Rats SD diet 
One-Generation 
Reproduction 
Toxicity Study   
64 (GD7-
PND49) 
(only pups 
examination
) 
 
0.3; 1.7; 6.4; 16; 
38; 72  
Pregnant dams 
(GD7- 
parturition) 
 
0.6; 3.5; 14; 37; 
84; 167 
  
Lactating dams 
(Pup PND 1 - 
PND 14)  
 
0.6; 3; 11; 29; 69; 
166  
F1 male; PND21-
PND50 
↑ weight (F1♂, 29) 
NTP tr 79, 
2007 [82] 
Genistein Rats   SD diet 
Multigenerational 
reproductive 
toxicology 
 
F0: From 
PND 42 to 
PND 140 (98 
days) 
 
F1: From 
conception 
to PND 140 
(161 days) 
F2: From 
conception 
to PND 140 
(161 days)                                                                       
F3: From 
conception 
to PND 21, 
fed control 
feed from 
PND 21 to 
PND 140 
(161 days 
total, 42 
days on 
dosed feed) 
 
F4: No 
exposure; 
control feed 
from 
conception 
to PND 140 
(161 days 
total, no 
dosed feed) 
 
F5: No 
exposure; 
control feed 
from 
conception 
to PND 21 
(42 days 
total, no 
dosed feed) 
m: 0; 0.03; 5; 25  
↓weight (F4♂, from 
parent exposed to 25-
50);  
NTP tr 539, 
2008 [83] 
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Genistein Rats   SD diet Carcinogenicity 
F0: From 
PND 42 until 
F1 weaning 
(77 days) 
F1 (F1C): 
From 
conception 
to 2 years 
(756 days) 
F1 (F1T140): 
From 
conception 
to PND 140 
(161 days), 
then fed 
control diet 
to 2 years 
F3 (F3T21): 
From 
conception 
to PND 21 
(42 days), 
then fed 
control diet 
to 2 years 
pregnant dams: 
0; 0.5; 9; 45; 
lacting dams: 
0.7; 15; 75; 
period prior to 
PND 140: 0.4;7; 
37; period 
between PND 
140 and the end: 
0.2; 4; 20 
↑ rel. Weight (F1C♂, 
20-37): ↑weight 
(F3T21♂, 45-75); ↓ rel. 
Weight (F3T21♂, 9-15) 
NTP tr 545, 
2007 [70] 
Genistein Rats Wistar diet Chronic toxicity 364 
5; 50; 500  
↓ rel weight (♂, 500 at 
132 and 364) 
Mc Clain et 
al., 2006 
[71] 
Bisphenol A Rats SD gavage 
Perinatal and 
Chronic toxicity 
In utero + 
PND1-21 (no 
dosing to 
365) 
0; 0.0025; 0.025; 
0.25; 2.5; 27 
↑ liver mononuclear 
cell infiltration (F1♀, 
0.0025; 25) 
 NTP RR 09; 
sept. 2018 
[86] 
Bisphenol A Rats SD gavage 
Perinatal and 
Chronic toxicity 
In utero + 
PND1-365 
0; 0.0025; 0.025; 
0.25; 2.5; 25 
↑liver hepato-
diaphragmatic nodule 
(F1♂,2.5); ↑ liver 
mononuclear cell 
infiltration (F1♂ 0.25; 
2.5) 
 NTP RR 09; 
sept. 2018 
[86] 
Bisphenol A Rats SD gavage 
Perinatal and 
Chronic toxicity 
In utero + 
PND1-21 (no 
dosing to 
730) 
0; 0.0025; 0.025; 
0.25; 2.5; 28 
no effect 
 NTP RR 09; 
sept. 2018 
[86] 
Bisphenol A Rats SD gavage 
Perinatal and 
Chronic toxicity 
In utero + 
PND1-730 
0; 0.0025; 0.025; 
0.25; 2.5; 26 
↑liver angiectasia 
(F1♂; 0.025) 
 NTP RR 09; 
sept. 2018 
[86] 
Bisphenol A Mice B6C3F1 diet Carcinogenicity 730 500; 750 
↑multinucleated giant 
hepatocytes (F♂, 500; 
750) 
NTP tr 215, 
1982 [66] 
Bisphenol A Rats SD gavage 
One-Generation 
Reproduction 
Toxicity Study   
GD6-PND90  
0.0025; 0.008; 
0.025; 0.08; 
0.26; 0.840; 2.7; 
100; 300 
↑ weigh (F1 ♀, 300, 
PND90); ↓ abs weight 
(F1♂ 
Delclos et 
al., 2016 
[39] 
Bisphenol A Mice CD-1 diet 
Multigeneration 
reproductive 
toxicology 
112 
0.003; 0.03; 0.3; 
5; 50; 600 
↑liver centrilobular 
hepatocyte 
hypertrophy; abs 
weight (F0♂, 50; 600) 
Tyl et al., 
2008 [37]  
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3.3 Results of in silico methodology 
 
From molecular docking to ERα, the molecular poses, the binding free energies of 
each compound and the MMGBSA values were obtained. These energies ranged 
from -11.3 to -7.2 kcal/mol and are listed in Table 3. The docking data showed that 
all tested compounds were able to bind the ligand binding domain (LBD) of ERα. 
17β-estradiol, the natural hormone, is the top scoring compound for both bind free 
energy and MMGBSA binding values. Zearalenone and Diethylstilbestrol can be 
classified as very competitive ligands with respect to 17β-estradiol, while the other 
chemicals can be classified as good binders (Genistein, Bisphenol A, DEHP and 
Methoxychlor) or weak binders (Vinclozolin and 4-nonylphenol). 
 
Table 3. Computed binding free energies of each ligand with hERα 
Ligand  XP GScore* MMGBSA dG Bind# Ki (M)° 
17β –estradiol -11.3 -78.6 4.6E-09 
Zearalenone -11.3 -57.2 4.8E-09 
Diethylstilbestrol -11.0 -59.1 8.4E-09 
Genistein -9.9 -48.4 4.9E-08 
Bisphenol A -9.7 -47.0 7.6E-08 
DEHP -9.4 -2 1.2E-07 
Methoxychlor -9.0 -37.8 2.5E-07 
Vinclozolin -8.3 -43.4 8.1E-07 
4-nonylphenol -7.2 -46.3 5.4E-06 
 
 
* Extra Precision Glide score: approximates a very close and entire systematic search for the conformational, 
orientational and positional space of the docked ligand. Glide utilizes a series of hierarchical filters to search for possible 
locations of the ligand in the active-site region of the receptor. 
# MM-GBSA, molecular mechanics-generalized Born surface area: calculates binding free energies for molecules by 
combining molecular mechanics calculations and continuum (implicit) solvation models (Implicit solvent models are 
often used to estimate free energies of solute‐solvent interactions and significantly improve the computational speed 
and reduce errors in statistical averaging that arise from incomplete sampling of solvent conformations. 
° Dissociation constant computed starting from empirical binding free energy values (XP GScore). The smallest value 
means that the compound has a larger affinity at lower concentration. 
Affinity is inversely proportional to the binding free energy. Smaller is the binding free energy value (the most negative), 
higher is the affinity. 
The dissociation constant (Ki) was computed starting from empirical binding free energy values (XP GScore), according 
to the following equation: ,  
where R represents the gas constant and T the temperature. Ki was computed starting from the binding free energy 
values at a fixed temperature (300 K). The smallest value means that the compound has a larger affinity at lower 
concentration. 
 
 
 
 iKRTG ln
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A carefully inspection of the Table 3 has highlighted some interesting differences 
in the affinity calculated by XP GScore and MMGBSA dG Bind , respectively. 
These differences in the affinities values between these two docking protocols were 
due to that MMGBSA docking protocol take into account also the solvation effect 
of the solvent (water molecules) towards the ligands, computing both the 
solvent/LBD and ligand/solvent interactions. In our results (Table 3), 17β-estradiol, 
as expected, showed the highest affinity values in both approaches as, being the 
physiological hormone was able to contrast the solvation effect. The other ligands 
had greater values of MMGBSA scores because they, in the modelling conditions 
set, were not able to displace the water molecules into the LBD. Indeed, the binding 
free energy of DEHP (as XP GLIDE SCORE) was in the same range of BPA and 
Genistein while MMGBSA dG values of DEHP had the highest value ( -2 
kcal/mol). Thus, DEHP seems to remain in a soluble condition and it is not able to 
displace the water molecules into the LBD. There is a concordance between in silico 
results and literature data, where DEHP showed a high affinity to androgen receptor 
[see paragraph 1.7]. Zearalenone showed a binding free energy similar to that of the 
17- β-estradiol but the MMGBSA score was less negative than the endogenous 
hormones because of the solvation effect. 
The dissociation constant (Ki) was computed starting from empirical binding free 
energy values (XP GScore), according to the following equation:  
 
where R represents the gas constant and T the temperature. Ki was computed 
starting from the binding free energy values at a fixed temperature (300 K). The 
smallest value means that the compound has a larger affinity at lower concentration. 
Then I retrieved from the literature the Ki values experimentally determined in vitro 
binding assay by other research groups (Table 4). These were compared with the 
computed Ki values to make a validation of the in silico molecular modelling 
approach. 
 
 
 
 
 
 
 iKRTG ln
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Table 4. in silico calculated Ki and experimental Ki from literature*  
Ligand Calculated Ki (M)# In vitro experimental Ki (M)#* 
17β –estradiol 4.6E-09 1.3E-10 
Zearalenone 4.8E-09 8.0E-10 
Diethylstilbestrol 8.4E-09 4..0E-11 
Genistein 4.9E-08 2..6E-9 
Bisphenol A 7.6E-08 1..95E-07 
Methoxychlor 2.5E-07 1.174E-06 
# The smallest value means that the compound has a larger affinity at lower concentration. 
*Kuiper et al., 1996, [10] 
 
 
From these comparisons, it could be noted that there is a good concordance between 
predicted and experimental values. Thus, the in silico Ki seems reliable and could 
be used as a parameter for the prediction of putative endocrine disruptor activity. 
17β-estradiol showed a very small Ki value in both experimental assays (data from 
literature), as well as in the in silico molecular docking. It is also known that 17β-
estradiol is a potent endocrine disruptor that causes several toxic effects such as the 
decreasing of weight of seminal vesicles at very low concentration (see table 2 of 
apical target of EDCs). For this reason, 17β-estradiol is used a positive control in 
toxicology. Experimental Ki of genistein was smaller than the computed ones but 
very close to the experimental Ki value of endogenous hormone, whereas it is 
similar to the computed Ki of estradiol. Based on this observation, genistein should 
decrease the weight of seminal vesicles as the 17β-estradiol does. However, from 
the well conducted and highly reliable NTP studies (reported in table 2 above), 
genistein does not display any effect on seminal vesicles; thus, even if genistein has 
a low Ki (computed and experimental) with a potential ED activity, it cannot be 
considered as 17β-estradiol in term of ED activity, but simply a good binder to ERα. 
The same observation could be done also for Bisphenol A, whereas the computed 
Ki is smaller than its experimentally calculated value and it is 1 order of magnitude 
greater of the computed Ki of estradiol. From the carcinogenesis NTP study of 2 
years treatment (see table 2, seminal vesicles) BPA does not alter the physiology of 
seminal vesicles as estradiol, although that study mice were treated with high doses 
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up to 25 mg/kg bw day. Thus, even if BPA binds with a good affinity to ERα, it has 
not the toxicant effects on the seminal vesicles observed with 17β-estradiol. 
On the contrary with what found with BPA, methoxychlor has the highest value of 
both Ki (calculated in silico and in vitro), thus it is a very weak binder. Nevertheless, 
Chapin et al., 1997 [54] found out that methoxychlor administered at 50 and 100 
mg/kg bw day from GD14 to PND 42 caused a decrease of testis, seminal vesicles 
and prostate weight leading to conclude that methoxychlor could affect the 
endocrine organs only at higher concentration compared to Estradiol [54]. 
Zearalenone is known to be an ED, and its Ki (both experimental and computed) 
are in the same range of 17β-estradiol. Zearalenone was not able to affect the weight 
of seminal vesicles but caused other alterations possibly ER-mediated. 
The data are indicating that both computed and experimental Ki could be properly 
used as a parameter to classify the chemicals according to their binding ability to 
ERα; however, in the light of the evidences regarding the lack of correlation 
between the binding ability (computed or experimental) and the ED effects 
observed in vivo, it can be concluded that the Ki parameters do not have a predictive 
value of the ED activity of the compounds. 
 
 
 
 
3.4 Results of in vitro bioluminescence imaging assay 
 
The ability of the selected compounds to transcriptionally activate ERα was tested 
in ERE-Luc B17 cells, a sub-clone of the breast cancer cell line MCF-7, stably 
transfected with a luciferase reporter system under control of an estrogen-regulated 
synthetic promoter [76]. Photon emissions were recorded and quantified by a CCD 
camera upon adding to the medium the substrate luciferin as described in material 
and methods. B17 cells were treated with increasing concentrations (6-10 
depending on the in vitro toxicity) of each compound. Photon emission values were 
acquired before treatment and at 6 and 48 hours; values were normalized on the 
photon emissions measured before treatment (set as 1). The EC50 values of ERα 
activation were calculated using GraphPad Prism v.7 program and are reported in 
Figure 9 and summarized in Table 5. 
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Figure 9. Graphical representation of fold induction (curve dose-response) and potency (EC50) calculated at 6 
and 48 hours after treatment with tested compounds.  
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Each data represents the bioluminescence of each doses tested, bars represent the average ± SEM. GraphPad 
Prism v. 7 was used. 
 
Then the chemicals were ranked for their estrogenic potency at 6 and 48 h treatment. 
At 6 h the results were as follows: 17β-estradiol > DES > zearalenone > genistein 
> bisphenol A > methoxychlor (Figure 10a and b). 4-nonylphenol concentrations 
were cytotoxic at both time of exposure. DEHP and vinclozolin did not activate the 
ERα (EC50 not detectable at both time of exposure). At 48 hours after treatment 
the potency rank did not change. The potency data revealed that the estrogenic 
potencies of 17β-estradiol, diethylstilbestrol, zearalenone did not significantly 
change in the time course from 6 to 48 hours, while the potency of genistein and 
bisphenol A decreased of one order of magnitude. EC50 of Methoxychlor, at 
micromolar concentrations, appeared to be stable at 6 hours and 48 hours. DEHP, 
Vinclozolin and 4-nonylphenol did not induce any activation of estrogen receptor 
(Figure 9; Table 5). These last findings are in line with the literature, where it is 
reported a preferential action on the androgen receptor (AR) signaling by DEHP 
and Vinclozolin [57-60], and the lack of estrogenic activity, in general, of 
alkylphenols [61]. 
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Figure 10 a. Ranking of EC50s values at 6 hours after treatment in B17 clone MCF-7 cell lines 
of selected compounds. 17β-estradiol (most potent) > DES > zearalenone > genistein > 
bisphenol A > methoxychlor. DEHP, Vinclozolin and 4-nonylphenol were not ranked because 
of the missing of estrogen receptor activation or cytotoxicity. 
 
 
 
Figure 10 b. Ranking of EC50s values at 48 hours after treatment in B17 clone MCF-7 cell 
lines with increasing concentrations of selected compounds. 17β-estradiol (most potent) > DES 
> zearalenone > genistein > bisphenol A > methoxychlor DEHP, Vinclozolin and 4-
nonylphenol were not ranked because of the missing of estrogen receptor activation or 
cytotoxicity. 
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Table 5) Potency and efficacy values of the selected compounds to 
activate the ERE-Luc system in B17 MCF-7 cell lines. The values 
of fold induction represent the maximum activation of our cellular 
reporter system. 17β-estradiol is the reference positive control.  
  POTENCY EFFICACY 
COMPOUND EC50 6h EC50 48h F.I. 6h F.I. 48h 
17ß - ESTRADIOL 3.50E-12 6.90E-12 2.80 4.60 
     
DIETHYLSTILBESTROL 3.40E-10 2.30E-10 5.40 5.70 
ZEARALENONE 4.00E-10 4.50E-10 3.42 5.30 
  
    
GENISTEIN 1.10E-09 4.70E-08 6.60 6.20 
BISPHENOL A 4.80E-08 3.20E-07 3.66 1.94 
METHOXYCHLOR 4.60E-06 4.90E-06 3.00 2.12 
  
    
BIS-(2-ETHYLHEXYL) PHTHALATE n. d n. d n.d n.d. 
4-NONYLPHENOL  n.d n. d n.d n.d. 
VINCLOZOLIN n.d n. d n.d. n. d 
EC50 6h = concentration of the chemical that gives half-maximal response 
detected at 6 hours of treatment; EC50 48h = concentration of the chemical that 
gives half-maximal response detected at 48 hours of treatment; F.I. 6h = fold 
induction (maximal luciferase activity) detected at 6 hours of treatment; F.I. 48h 
= fold induction (maximal luciferase activity) detected at 48 hours of treatment. 
 
 
This work for the first time analysed the ER activity in time; the results indicated 
that while the rank of the potency did not change, the potency itself for some 
compound decreased during time suggesting a depotentiation mechanism is 
operating for some but not all the compound tested. Initially, it was hypothesized 
that this observation could be due to the compound metabolism that could be 
different among the compounds. To test the hypothesis, a LC-MS analysis was 
performed by the Laboratory of Mass-Spectrometry of Prof.ssa Donatella Caruso. 
Analysis were done on the medium and on the cellular total extracts of MCF7-B17 
treated with Bisphenol A, Zearalenone and Genistein at 6 and 48 hours. 
Qualification and quantification of the parental compounds by specific analytical 
condition set up in LC-MS technique (these data are shown in APPENDICES 
section to this thesis). These analytical data completely ruled out the possibility that 
the depotentiation mechanism was due to breakdown of the molecules, while it 
appears that was more likely due to changes at transcriptional level occurring on 
the receptor in time. 
 58 
 
In all previous experiments, the ability of a compound to activate or inhibit ER was 
considered at a single time point. Taking into account this static observation, the 
rank of the potency at 6 or at 48 hours (Figure 10 a and b) compared with the ED 
effects observed in vivo (Table 2) of the different compounds gave similar non-
predictive results for ED activity as those obtained with the calculated (and 
experimental) Ki parameter (see paragraph 3.2). For example, considering the 
potency of genistein and zearalenone at 6 hours, they are potent ER activators while 
only zearalenone displays a potent ED effects (Table 2). 
The dynamic analysis of ER activation allows to define novel parameters for the 
compound action through the receptor taking into account the change in potency 
and efficacy in time. By analysing the single parameter in time (potency or efficacy) 
and ranking the substances based on the magnitude of decrease observed can 
already discriminate from active EDs like 17β-estradiol, diethylstilbestrol and 
zearalenone from those that display weak or none ED effect genistein, bisphenol A 
and methoxychlor (Table 6a). While the efficacy table (Table 6b) is less prompt to 
highlight the differences observed as ED effects between genistein and the other 
disruptors. By combining the dynamic of potency and efficacy parameters these 
differences were magnified (Table 7) and ranking the compounds with a parameter 
which take into account the variation of potency and efficacy as well as the absolute 
value of efficacy after 48 h, it is possible to observe a clear classification of active 
ED compounds with those that does not have effect (genistein) or have effects only 
at very high doses (e.g. methoxychlor). 
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Table 6a. Ranking of selected chemicals based on the magnitude of the potencies (EC50s) 
variations. The right column reported the magnitude of the potencies variations during the time 
course from 6 to 48 hours. The colours represent the relationship between the ability to activate 
the estrogen receptor and the endocrine disrupting activity (ED) observed in vivo on male 
reproductive organs. Red = very high ED; Orange = high ED; Green = no-ED 
COMPOUND -log potency 6h -log potency 48h 
potency 
decreasing/increasing 
DIETHYLSTILBESTROL 9.47 9.64 0.17 ↑ 
ZEARALENONE 9.40 9.35 -0.05 ↓ 
   
 
17ß-ESTRADIOL 11.46 11.16 -0.29↓ 
   
 
GENISTEIN 8.96 7.33 -1.63↓↓ 
BISPHENOL A 7.32 6.49 -0.82↓ 
METHOXYCHLOR 5.34 5.31 -0.03 
 
 
Table 6b. Ranking of selected chemicals based on the magnitude of the efficacy variation. The 
right column reported the quantification of the efficacy variations during the time course from 6 
to 48 hours.  
The colours represent the relationship between the ability to activate the estrogen receptor and 
the endocrine disrupting activity (ED) observed in vivo on male reproductive organs. Red = ED; 
Green = no - ED 
COMPOUND efficacy 6h efficacy 48h 
Efficacy 
decreasing/increasing 
   
 
ZEARALENONE 3.42 5.30 1.88 ↑ 
17ß-ESTRADIOL 2.80 4.60 1.80↑ 
DIETHYLSTILBESTROL 5.40 5.70 0.30 ↑ 
   
 
GENISTEIN 6.60 6.20 -0.4 
BISPHENOL A 3.66 1.94 -1.72↓ 
METHOXYCHLOR 3.00 2.12 -0.88↓ 
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Table 7. Classification of ED compounds based on the combination of the variation of potency and efficacy in 
the time course with the absolute value of efficacy after 48h. The colours represent the relationship with the 
endocrine disrupting activity (ED) observed in vivo on male reproductive organs. Red = ED; Green = no-ED. 
 
COMPOUND 
RATIO POTENCY 
48/6 
RATIO EFFICACY 
48/6 
RATIO POTENCY*RATIO 
EFFICACY 
RATIO POTENCY*RATIO 
EFFICACY*EFFICACY AT 48H 
ZEARALENONE 0.99 1.55 1.54 8.17 
     
17-ß ESTRADIOL 0.97 1.64 1.6 7.36 
     
DIETHYLSTILBESTR
OL 
1.02 1.06 
1.07 
6.12 
     
GENISTEIN 0.82 0.94 0.77 4.76 
     
METHOXICHLOR 0.99 0.71 0.7 1.49 
BISPHENOL A 0.89 0.53 0.47 0.91 
 
 
Thus, the combination of the variation of the potency and the efficacy “normalized” 
respect to the efficacy values at 48h was successfully used in discriminating 
positive and negative compounds for their endocrine disrupting activity as showed 
in table 7. It must be noted that compounds with no ED effect in vivo such as BPA 
or with a putative ED effect only at high level of exposure (not relevant for the 
humans), such as methoxychlor, have a very low score (right column) when 
compared to chemicals with known ED effect in vivo (estradiol, DES, zearalenone). 
Thus, these chemicals occupied the lowest position in table 7 (green lanes), and by 
this classification, resulted very interesting the score of genistein. It follows the 
score of DES, but it is higher than methoxychlor and BPA. Genistein has not any 
ED effect in vivo even if it is a good binder of ER. So, the position of this 
phytoestrogen could represent a putative threshold of non- concern for ED effect. 
Over this threshold there is ED effect. On the contrary below this threshold the 
chemical could not have any ED effect. 
This in vitro classification fitted well with the in silico outcome where the strongest 
binders where ranked in the first position. 
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From these data, we may conclude that the novel dynamic ER transactivation assay 
is best marker of an ED activity than the classical transactivation or binding 
(computational or in silico) assays. 
 
 
3.5 Results of in vivo bioluminescence imaging 
experiments 
 
In transgenic reporter mice [76] already described in material and methods section, 
similar reporter-based biosensors like the one described in the transactivation assay 
were inserted in the genome of the mouse. In these reporter mice the luciferase 
expression is proportional to the activity of ER (ERE-Luc), NFkB (NFkB-Luc) rand 
Nrf2 (ARE-Luc), thus reporting the modulation of estrogen receptor, inflammation 
and oxidative stress pathway in any mouse tissue. To test the effects of Zearalenone, 
Bisphenol A, 17β-estradiol on these signals 4 reporter mice/experimental group 
were treated daily with two dosages of each substance administered in the drinking 
water for 21days. The compounds and their doses were chosen combining data 
obtained from the literature with in vitro results (see also Table 2). Since testing 
many doses was not possible for budget reason, we decided to choose a threshold 
dose, more realistic in term of human exposure, and a high dose, to force the system 
and see an effect, in case there was a low sensitivity. Zearalenone was both a strong 
binder (Ki was 4.8E-09 M) and activator of ER (EC50s were 4.00E-10 M and 4.50E-
10 M at 6 and 48 hours, respectively), similarly to endogenous hormone values. 
This mycotoxin is known to be an endocrine disruptor because of the adverse effect 
on female reproductive tract of immature pigs, thus it was interesting to investigate 
if it could be a putative ED on male reproductive organs. The doses of zearalenone 
were obtained considering to cover a low range of active concentrations retrieved 
in the literature (see table 2). Bisphenol A was a good binder in silico model (Ki 
was 7,6E-08 M) and moderate activator of ER in vitro assay (EC50s were 4.80E-08 
M and 3.20E-07 M at 6 and 48 hours, respectively). BPA was selected instead of 
Genistein, which showed good results from the previously approaches, because of 
this phytoestrogen is considered to have no ED effect or toxicity to human 
according to EFSA’s opinion [73], even if it has an interesting action on ER such 
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as demonstrated in our in silico and in vitro experiments. The BPA doses were 
selected to cover a low dose range of putative active concentrations retrieved in the 
literature (see also table 2). 
The activation of these pathways was measured daily in each single mouse by 
bioluminescence in vivo imaging (see material and methods) for the 21 days of the 
experiment. After 21 days the animals were sacrificed, and organs were taken for 
ex vivo bioluminescence imaging analysis of the photon emission. Photon emission 
from the mouse body was quantified from the genital and abdominal areas in vivo 
and from prostate, testis, seminal vesicles and intestine ex vivo. Photon emission 
levels in time were normalized on the value measured before treatment (set to 1) in 
each animal. I have considered as parameters of activation: I) the acute effects 
observed after 24 hours, ii) the AUC over the 21 days, iii) the emission of the final 
day (day 21) and iv) the ex vivo photon emission measured from the explanted 
organs.  
In the genital area the bioluminescence activity of estrogen receptor ERE-Luc at 
day 1 (acute activation), showed the presence of a trend of BPA10, BPA100; 
ZEA150, E10 and E100. Instead, in the abdominal area the ZEA150 showed a 
marked induction.  
The ER signaling was clearly activated after 24 hours in the abdominal area by high 
doses of ZEA and E2 given per os, while no activation was visible by any treatment 
in the genital area of the mouse (Figure 11). Similar data were obtained analysing 
the AUC of the activation over the 21 days-acquisitions (Figure 12). The acquisition 
at day 21 (Figure 13) was demonstrating a persistent effect of ZEA and E2 on the 
abdominal area and a non-significant trend of increase the activity in the genital 
area for some treatment.  
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Figure 11. Quantification of bioluminescence of hormonal ERE-Luc pathway in genital area (left panel) and 
abdominal area (right panel) on day 1 as acute activation. 
GENITAL AREA ABDOMINAL AREA 
ACTIVITY OF ESTROGEN RECEPTOR ERE-Luc 
ACTIVATION ON DAY 1 (ACUTE ACTIVATION) 
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V = vehicle; BPA10 = bisphenol A 10 mg/Kg/day; BPA100 = bisphenol A 100 mg/Kg/day; ZEA10 = zearalenone 10 
mg/Kg/day; ZEA150 = zearalenone 150 mg/Kg/day; E10 = 17β-estradiol 10 μg/Kg/day; E100 = 17β-estradiol 100 
μg/Kg/day. The values represent the means of photon emissions  SEM calculated with GraphPad Prism v.7. *p<0.05 
vs vehicle applying Ordinary one-way ANOVA plus Bonferroni's multiple comparisons test. 
 
 
 
 
In the chronic activation phase (Figure 12), the values of interactions with the 
reporter system are expressed as Area Under the Curve (AUC) calculated by the 
program GraphPad Prism v.7. In the genital area there was not a significant activity 
even if ZEA150 seemed to maintain its activation as on day 1. In the ERE-Luc of 
abdominal area E100 finally produced an important statistically significant 
induction of ER versus the vehicle (p< 0.05). On the contrary to day 1, ZEA150 
showed a good activation. The other doses did not produce any induction. 
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Figure 12. Quantification of bioluminescence of hormonal ERE-Luc pathway in genital area (left panel) and 
abdominal area (right panel) over 21 days of treatment as chronic activation. 
GENITAL AREA ABDOMINAL AREA 
ACTIVITY OF ESTROGEN RECEPTOR ERE-Luc 
CHRONIC ACTIVATION (AUC) 
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V = vehicle; BPA100 = bisphenol A 100 mg/Kg/day; ZEA10 = zearalenone 10 mg/Kg/day; ZEA150 = zearalenone 
150 mg/Kg/day; E10 = 17β-estradiol 10 μg/Kg/day; E100 = 17β-estradiol 100 μg/Kg/day. 
The values represent the means of photon emissions ± SEM calculated with GraphPad Prism v.7. *p< 0.05 vs 
vehicle calculated applying Ordinary one-way ANOVA plus Bonferroni's multiple comparisons test. 
 
In the analysis of terminal day 21 (Figure 13), only in the abdominal area the 
treatment E100 prolonged its activity, while the other treatments decreased the 
potency till control baseline in both observed area 
 
 
Figure13. Quantification of bioluminescence of hormonal ERE-Luc pathway in genital area (left panel) and 
abdominal area (right panel) on day 21 as terminal activation. 
GENITAL AREA ABDOMINAL AREA 
ACTIVITY OF ESTROGEN RECEPTOR ERE-Luc 
ACTIVITY ON DAY 21 
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 V = vehicle; BPA100 = bisphenol A 100 mg/Kg/day; ZEA10 = zearalenone 10 mg/Kg/day; ZEA150 = zearalenone 
150 mg/Kg/day; E10 = 17β-estradiol 10 μg/Kg/day; E100 = 17β-estradiol 100 μg/Kg/day. The values represent 
the means of photon emissions ± SEM calculated with GraphPad Prism v.7. *p< 0.05 vs. the vehicle calculated 
applying Ordinary one-way ANOVA plus Bonferroni's multiple comparisons test.  
 
 
The analysis of each single organ ex vivo demonstrated a weak trend of receptor 
activation in testis (Figure 14) and prostate (Figure 15). ZEA150 had a good but no 
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statistically significant activation in seminal vesicles (Figure 15). No interesting 
signaling were detected in the seminal vesicles by other treatments (Figure 15).  
 
Figure 14. Quantification of bioluminescence of hormonal ERE-Luc 
pathway in testis by ex vivo analysis as local activation. 
GENITAL AREA 
ACTIVITY OF ESTROGEN RECEPTOR ERE-Luc 
DETAIL: TESTIS 
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Figure 15. Quantification of bioluminescence of hormonal ERE-Luc pathway in seminal vesicles (left panel) and 
prostate (right panel) by ex vivo experiment as local activation. 
GENITAL AREA 
ACTIVITY OF ESTROGEN RECEPTOR ERE-Luc 
DETAIL: SEMINAL VESICLES DETAIL: PROSTATE 
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V = vehicle; BPA100 = bisphenol A 100 mg/Kg/day; ZEA10 = zearalenone 10 mg/Kg/day; ZEA150 = zearalenone 150 
mg/Kg/day; E10 = 17β-estradiol 10 μg/Kg/day; E100 = 17β-estradiol 100 μg/Kg/day. 
The values represent the means of photon emissions ± SEM and analysed by Ordinary one-way ANOVA plus 
Bonferroni's multiple comparisons test. 
 
 
 
V = vehicle; BPA100 = bisphenol A 100 mg/Kg/day; ZEA10 = 
zearalenone 10 mg/Kg/day; ZEA150 = zearalenone 150 
mg/Kg/day; E100 = 17β-estradiol 100 μg/Kg/day. The values 
represent the means of photon emissions ± SEM calculated 
with GraphPad Prism v.7 and analysed by Ordinary one-way 
ANOVA plus Bonferroni's multiple comparisons test.  
 
 
 
 
 
The alues repr sent the means of photon emissions ± SEM and 
analyzed by Ordinary one-way NOVA pus Bonferroni's multiple 
comparisons test. 
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In the intestine, BPA100 and E10 showed an receptorial ER activation but as the 
other doses, they did not produce a significant ER signaling (Figure 16). The 
activation observed by in vivo imaging analysis of E2 and ZEA150 in the 
abdominal area were not due to the intestine but possibly are mediated by other 
organs, e.g. kidney, live or spleen which express also the estrogen receptors. 
 
Figure 16. Quantification of bioluminescence of hormonal ERE-Luc pathway in 
intestine tract by ex vivo experiment as local activation. 
ABDOMINAL AREA 
ACTIVITY OF ESTROGEN RECEPTOR ERE-Luc 
DETAIL: INTESTINE 
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No significant activation of the inflammatory (NFkB) pathway was observed after 
acute administration of the compounds in both genital and abdominal areas even if 
E10 seemed to produce an interesting signaling (Figure 17).  
 
 
V = vehicle; BPA100 = bisphenol A 100 mg/Kg/day; ZEA10 = zearalenone 10 
mg/Kg/day; ZEA150 = zearalenone 150 mg/Kg/day; E10 = 17β-estradiol 10 
μg/Kg/day; E100 = 17β-estradiol 100 μg/Kg/day. 
The values represent the means of photon emissions ± SEM and analyzed by 
Ordinary one-way ANOVA plus Bonferroni's multiple comparisons test. 
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Figure 17. Quantification of bioluminescence of inflammatory (NFkB) pathway in genital area (left panel) 
and abdominal area (right panel) on day 1 as acute activation.  
GENITAL AREA ABDOMINAL AREA 
ACTIVITY OF NFkB-Luc pathway 
ACTIVATION ON DAY 1 (ACUTE ACTIVATION) 
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V = vehicle; BPA100 = bisphenol A 100 mg/Kg/day; ZEA10 = zearalenone 10 mg/Kg/day; ZEA150 = 
zearalenone 150 mg/Kg/day; E10 = 17β-estradiol 10 μg/Kg/day; E100 = 17β-estradiol 100 μg/Kg/day. 
The value represents the means of photon emissions ± SEM and analyzed by Ordinary one-way ANOVA plus 
Bonferroni's multiple comparisons test. 
 
The AUC analysis, which represents the whole activation of reporter system over 
the 21 days of repeated treatments, showed a clear activation of the inflammatory 
(NFkB) pathway upon administration of the highest dose of zearalenone, but only 
in the genital area (Figure 18).  
 
Figure 18. Quantification of bioluminescence of inflammatory (NFkB) pathway in genital area (left panel) and abdominal 
area (right panel over 21 days of treatment as chronic activation. 
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ACTIVITY OF NFkB-Luc pathway 
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V = vehicle; BPA100 = bisphenol A 100 mg/Kg/day; ZEA10 = zearalenone 10 mg/Kg/day; ZEA150 = zearalenone 150 
mg/Kg/day; E10 = 17β-estradiol 10 μg/Kg/day; E100 = 17β-estradiol 100 μg/Kg/day. 
The values represent the means of photon emissions ± SEM and analyzed by Ordinary one-way ANOVA plus 
Bonferroni's multiple comparisons test. 
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Interestingly, at day 21 the NFkB pathway was found significantly active in the 
genital and abdominal area of the highest dose of the zearalenone group and on the 
low-dose group in the abdominal area. No other significant activation could be 
detected with the other treatment (Figure 19).  
 
Figure 19. Quantification of bioluminescence of inflammatory (NFkB) pathway in genital area (left panel) and 
abdominal area (right panel) on day 21 as terminal activation. 
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The ex vivo bioluminescence imaging analysis of inflammatory pathway 
demonstrated that the significant activations produced by ZEA150 in the genital 
area were likely due to the NFkB signalling in the prostate (Figure 20). The other 
treatments did not produce any significant activation. 
  
 
 
 
 
 
 
 
 
 V = vehicle; BPA100 = bisphenol A 100 mg/Kg/day; ZEA10 = zearalenone 10 mg/Kg/day; ZEA150 = zearalenone 
150 mg/Kg/day; E10 = 17β-estradiol 10 μg/Kg/day; E100 = 17β-estradiol 100 μg/Kg/day. The values represent the 
means of photon emissions ± SEM and analyzed by Ordinary one-way ANOVA plus Bonferroni's multiple 
comparisons test (*p < 0.05 vs vehicle and abdominal area *p< 0.05 vs. vehicle). 
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Figure 20. Quantification of bioluminescence of inflammatory (NFkB) pathway in testis, seminal vesicles and prostate by 
ex vivo experiment as local activation. 
GENITAL AREA 
ACTIVITY OF NFkB-Luc pathway 
DETAIL: TESTIS DETAIL: SEMINAL VESICLES 
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V = vehicle; BPA100 = bisphenol A 100 mg/Kg/day; ZEA10 = zearalenone 10 mg/Kg/day; ZEA150 = zearalenone 150 
mg/Kg/day; E10 = 17β-estradiol 10 μg/Kg/day; E100 = 17β-estradiol 100 μg/Kg/day. 
The values represent the means of photon emissions ± SEM and analysed by Ordinary one-way ANOVA plus 
Bonferroni's multiple comparisons test. Testis: *p < 0.051 vs. vehicle; prostate *p < 0.05 vs. vehicle. 
 
 
 
The findings that ZEA150 was able to activate the inflammatory pathway in the 
genital area with a specific local effect in the prostate was very particular. Since no 
activity of the ER signaling was detected in the prostate by both doses of ZEA150, 
we may conclude that the strong NFkB activity elicited over the 21 days-treatment 
was due to the activation of other receptors (e.g. androgen receptor).  
 
 
In the ex vivo NFkB analysis of intestine no significant signal was detected. This 
result explains that highest activation of ZEA150 at day 21 maybe was due to other 
organs in abdominal area (e.g. kidney, spleen, liver). 
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Figure 21. Quantification of bioluminescence of inflammatory (NFkB) pathway 
in intestine tract by ex vivo experiment as local activation. 
ABDOMINAL AREA 
ACTIVITY OF ESTROGEN RECEPTOR NFkB-Luc 
DETAIL: INTESTINE 
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About the quantification of bioluminescence in the ARE-Luc reporter mice for the 
investigation of the activation of oxidative stress pathway, no significant signaling 
of the ARE-Luc pathway were observed after acute or chronic administration of the 
compounds (Figures 22-24, 26). Although an interesting activation in the ARE-Luc 
reporter mouse model was observed in the prostate upon treatment with zearalenone 
but it was not supported by statistical analysis (Figure 25).  
Those data are suggesting that this oxidative stress pathway is not involved in the 
toxicity as reported for these compounds in previous in vivo experiments. 
 
 
 
 
 
V = vehicle; BPA100 = bisphenol A 100 mg/Kg/day; ZEA10 = zearalenone 10 
mg/Kg/day; ZEA150 = zearalenone 150 mg/Kg/day; E10 = 17β-estradiol 10 
μg/Kg/day; E100 = 17β-estradiol 100 μg/Kg/day. The values represent the means of 
photon emissions ± SEM and analyzed by Ordinary one-way ANOVA plus 
Bonferroni's multiple comparisons test. 
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Figure 22. Quantification of bioluminescence of oxidative stress (ARE-Luc) pathway in genital area (left panel) 
and abdominal area (right panel) on day 1 as acute activation.  
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V = vehicle; BPA10 = 10 mg/Kg/day; BPA100 = bisphenol A 100 mg/Kg/day; ZEA10 = zearalenone 10 mg/Kg/day; 
ZEA150 = zearalenone 150 mg/Kg/day; E10 = 17β-estradiol 10 μg/Kg/day; E100 = 17β-estradiol 100 μg/Kg/day. 
The values represent the means of photon emissions ± SEM and analyzed by Ordinary one-way ANOVA plus 
Bonferroni's multiple comparisons test. 
 
Figure 23. Quantification of bioluminescence of oxidative stress (ARE-Luc) pathway in genital area (left panel) and 
abdominal area (right panel over 21 days of treatment as chronic activation. 
GENITAL AREA ABDOMINAL AREA 
ACTIVITY OF ARE-Luc pathway 
CHRONIC ACTIVATION (AUC) 
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V = vehicle; BPA10 = 10 mg/Kg/day; BPA100 = bisphenol A 100 mg/Kg/day; ZEA10 = zearalenone 10 mg/Kg/day; 
ZEA150 = zearalenone 150 mg/Kg/day; E10 = 17β-estradiol 10 μg/Kg/day; E100 = 17β-estradiol 100 μg/Kg/day. The 
values represent the means of photon emissions ± SEM and analyzed by Ordinary one-way ANOVA plus 
Bonferroni's multiple comparisons test. 
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Figure 24. Quantification of bioluminescence of oxidative stress (ARE-Luc) pathway in genital area (left panel) and 
abdominal area (right panel) on day 21 as terminal activation. 
GENITAL AREA ABDOMINAL AREA 
ACTIVITY OF ARE-Luc pathway 
ACTIVITY ON DAY 21 
 
v
E
1
0
0
 
e
1
0
 
z
e
a
1
5
0
 
z
e
a
1
0
 
b
p
a
1
0
0
 
b
p
a
1
0
 
0 .0
0 .5
1 .0
1 .5
c
ts
/c
m
2
s
/s
r
 
 
v 
B
P
A
10
0 
ZE
A
10
ZE
A
15
0 
E1
0 
E1
00
0
1
2
3
4
5
c
ts
/c
m
2
s
/s
r
 
V = vehicle; BPA10 = 10 mg/Kg/day; BPA100 = bisphenol A 100 mg/Kg/day; ZEA10 = zearalenone 10 mg/Kg/day; 
ZEA150 = zearalenone 150 mg/Kg/day; E10 = 17β-estradiol 10 μg/Kg/day; E100 = 17β-estradiol 100 μg/Kg/day. The 
values represent the means of photon emissions ± SEM and analyzed by Ordinary one-way ANOVA plus Bonferroni's 
multiple comparisons test. 
 
Figure 25. Quantification of bioluminescence of oxidative stress (ARE-Luc) pathway in testis, seminal vesicles, prostate 
from ex vivo experiment as local activation in local activation. 
GENITAL AREA 
ACTIVITY OF ARE-Luc pathway 
DETAIL: TESTIS DETAIL: SEMINAL VESICLES 
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V = vehicle; BPA10 = 10 mg/Kg/day; BPA100 = bisphenol A 100 mg/Kg/day; ZEA10 = zearalenone 10 mg/Kg/day; 
ZEA150 = zearalenone 150 mg/Kg/day; E10 = 17β-estradiol 10 μg/Kg/day; E100 = 17β-estradiol 100 μg/Kg/day. 
The Value are means ± SEM and analyzed by Ordinary one-way ANOVA plus Bonferroni's multiple comparisons 
test. 
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Figure 26. Quantification of bioluminescence of oxidative stress (ARE-
Luc) pathway in intestine tract from ex vivo experiment as local 
activation in local activation. 
Abdominal ARE-Luc pathway: INTESTINE  
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V = vehicle; BPA100 = bisphenol A 100 mg/Kg/day; ZEA10 = zearalenone 
10 mg/Kg/day; ZEA150 = zearalenone 150 mg/Kg/day; E10 = 17β-
estradiol 10 μg/Kg/day; E100 = 17β-estradiol 100 μg/Kg/day. The values 
represent the means of photon emissions ± SEM and analyzed by 
Ordinary one-way ANOVA plus Bonferroni's multiple comparisons test. 
 
 
 
 
These findings indicate some remarkable correlation with the literature. Indeed, the 
weak evidences of ARE-Luc activation and significant activation of the NFkB-Luc 
pathways in the genital area with a specific focus on the prostate by the highest dose 
of zearalenone (150 mg/kg /day), match with the toxicological findings reported in 
the NTP study (NTP tr 235) (Table 2). In that study, mice and rats were fed for 90 
day or 2 years with a wide range of concentrations (1 to 450 mg/kg bw day) of 
zearalenone. ZEA elicited adverse effects, such as an increase of incidence of 
squamous metaplasia in the prostate of B6C3F1 mice at 150 mg/kg bw day; 
inflammation in the prostate of F344/N rats at 1 mg/kg bw day and hyperplasia at 
27-290 mg/kg bw day and an increase of atrophy in seminal vesicles and testis in 
both species, at low and at a higher dose (1-150 mg/kg bw day). Some evidence of 
cytoplasmic vacuolization increase (1.25; 2.5 mg/kg bw day) occurred in rats in the 
carcinogenicity study (Table 2). 
The NFkB-Luc reporter mice seemed to be predictive of the indirect toxicological 
mechanisms of zearalenone, through the inflammatory pathway in the genital area.  
 74 
 
In addition, zearalenone confirmed to be an ER activator only in the abdominal area 
of ERE-Luc mice (no activation in the genital area). This finding was not observed 
locally in the intestine, so other organs were involved in the estrogenic activation. 
These organs could be the liver or the kidney. Indeed, in the above mentioned NTP 
study [66], zearalenone was found to cause some toxicity to that organs. 
Bisphenol A, for which there are controversial data in the literature, did not produce 
a significant activation in both the areas and in the ex vivo analysis, again in 
agreement with in silico/in vitro results. 
The lack of ER activation of estradiol in the genital area was possibly due to oral 
administration of the compound in drinking water. This compound exerts a potent 
adverse effect in toxicological studies when administered by injection. 
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Discussion and Conclusive remarks  
 
The extreme attention to the health of citizens and consumers to the involuntary 
exposure (through food, water, air) to endocrine disruptor, i.e. those substances 
capable of causing damage to any component of the endocrine system, has led to 
an increasingly stringent regulatory pressure in Europe. 
Since the endocrine system responds physiologically with homeostatic mechanisms 
in response to external stimuli, it becomes important to identify and distinguish 
between substances able to cause a damage a harm and substances that interact with 
the body in a transitory manner causing an adaptive response without toxic 
consequences. 
Being unlikely to solve the hormonal activity adaptation/ disruption issue with just 
experimental assay, we have tried to address the hazard characterization of 
substances with hormonal activity by the development of an integrated strategy of 
testing based on the combination of results of a hierarchy of different 
methodologies such as in silico models, in vitro and in vivo bioluminescence 
imaging assays.  
The selected molecules ranged from known (DES) to suspected (BPA) endocrine 
disruptors and included both synthetic (DEHP) and natural (genistein) substances. 
As positive control 17β-estradiol has been used. 
The first step used was in silico analysis with evaluation of the possible binding of 
selected substances to the estrogen alpha receptor to support the hypothesis that 
their hormonal activity occurred through a receptorial mechanism. 
This approach is commonly used and is also part of the first level of investigation 
suggested by EFSA / ECHA in the recognition of EDCs.  
Interest in computer-aided methods for investigations in the biological field has 
increased significantly in recent years. Despite their apparent simplicity, the results 
that derive from this approach must be carefully weighted and provide an indication 
of how to proceed further in the investigation rather than a definitive indication of 
a biological effect. 
The computational methodology estimated different values of affinity of each 
ligand to hER Ligand Binding Domain (LBD). The value of using two different 
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approaches (XP Glide Score and MMGBSA) allowed to be taken into account 
solvation. That has meant that the MMGBSA docking protocol the solvation effect 
of the solvent (water molecules) towards the ligands, computing both the 
solvent/LBD and ligand/solvent interactions. The estradiol showed the best affinity 
values in both approaches as, being the endogenous hormone, is able to contrast the 
solvation effect. 
The other ligands had greater values of MMGBSA scores because they, in the 
modelling conditions set, were not able to displace the water molecules into the 
LBD. Indeed, the binding free energy of DEHP (as XP GLIDE SCORE) was in the 
same range of BPA and Genistein while MMGBSA dG values of DEHP had the 
highest value ( -2 kcal/mol). Thus, DEHP seems to remain in a soluble condition 
and it is not able to displace the water molecules into the LBD. There is a 
concordance between in silico results and literature data, where DEHP showed a 
high affinity to androgen receptor [see paragraph 1.7]. Zearalenone showed a 
binding free energy similar to that of the 17- β-estradiol but the MMGBSA score 
was less negative than the endogenous hormones because of the solvation effect. 
The dissociation constant (Ki) values calculated from the XP GLIDE SCORE fits 
well with the Ki experimentally determined in vitro binding assay by other research 
groups. Thus, the computed Ki has been chosen as parameter for the prediction of 
putative endocrine disrupting activity (ED) taking into account the ED activity data 
in literature. However, the lack of correlation between the computed and 
experimental Ki and experimental ED activity retrieved in literature for all 
chemicals (only estradiol and zearalenone have similar affinity to ER and literature 
evidences of ED activity; genistein has a good Ki values but not ED activity such 
as BPA and methoxychlor), did not allow a prioritization of the investigated 
chemicals for ED activity through the results of their affinity. 
In the next step, to check if the receptor binding was well correlated with the 
hormonal activity, the ER Reporter gene assay was performed, based on the ability 
of a compound to stimulate ER-dependent transcriptional activity in genetically 
engineered mammalian cells. The cell lines are MCF-7 cells which express human 
endogenous ERα. The cells are transformed (transfected) by introducing vectors 
containing DNA sequences for the receptor, along with EREs linked to a reporter 
gene, and the reporter gene itself. The reporter gene used in human cancer cells 
usually codes for luciferase (CALUX, chemically activated luciferase expression). 
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In the transactivation the EDCs show the estrogenic potency calculated as EC50, in 
respect to the positive control, 17β-estradiol. This system has enabled us to evaluate 
the kinetic and the biological consequences of cellular activation in the same cell 
monolayer, also taking into account the potential metabolism of the compounds or 
their possible degradation. In fact, a modification of the cellular response could also 
be attributed to the appearance of +/- active metabolites or to the degradation of the 
parent compounds. As mentioned in the results section, all compounds were stable 
and not significantly metabolized during the cell incubation period. 
Three factors were taken into consideration, power, efficacy and trend over time. 
The in vitro dynamic ER activation showed that for some chemicals (genistein, 
BPA, methoxychlor), the potency (EC50) and the efficacy (fold induction) changed 
over time, but not for estradiol, zearalenone and DES. 
Considering that estradiol, zearalenone and DES certainly have an activity in the 
animal and in man as endocrine disruptors, the duration of effect parameter 
combined with power and efficacy are likely to be associated in predicting the 
hormonal activity. Together with receptor affinity and the ability to induce a 
biological response, it also seems relevant how long the response is lasting. By 
consequence, the combination of the variation of the potency response and the 
efficacy, “normalized” for the efficacy at 48h, was successfully used in 
discriminating positive and negative compounds for their endocrine disrupting 
activity. 17β-estradiol, DES and zearalenone were put at the top of the list because 
of their ED effect observed in vivo, genistein resulted to represent a putative 
threshold of no-concern for ED activity, in supporting published data, while 
methoxychlor and BPA are definitely not considered a priority in terms of ED 
activity. This in vitro classification fitted well with the in silico outcome, since the 
strongest estrogen receptor binders where ranked in the first position. Besides, was 
no possible to calculate EC50s for 4-nonylphenol, DEHP and vinclozolin, not 
making possible to classify them as ED, totally in agreement with in silico results 
and in line with literature data (vinclozolin is mainly an androgen antagonist). 
The third step of our stepwise approach was intended to verify in vivo the 
interaction of selected chemicals with the estrogen receptor and in addition the 
activation of other pathways triggering primary harmful effects. 
We used three reporter mice designed in order to evaluate the response of some 
compounds to activate ER and causing oxidative stress and inflammation. The aim 
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of this phase was to investigate whether oxidative stress and inflammation could be 
correlated, and at which extent, with a ED response by analysing the activity of the 
compounds in a spatio-temporally manner (the bioluminescence image represents 
a picture of how far the receptor activation as photon emissions in the specific area 
(tissue), is extended at that precise time of observation.  
We choose to test zearalenone (well-known endocrine disruptor and clearly 
identified as such by our in silico-in vitro approach), and BPA for which there are 
controversial data in the literature and that our approach has negatively classified 
as an ED. 
Briefly, zearalenone disrupts oestrous cycle, ovulation, conception and 
implantation, cause embryonic death, reduce fetal weight and litter size and to 
impair neonatal survival on female pigs [24; 25]. BPA, at high doses, has raised 
concern for its high production volume and for the evidence of toxicity in animal 
studies mainly on reproductive and developmental systems, liver, kidney and some 
evidence in mammary gland [16,36-39]. 
Our data shows that zearalenone has been active on ER pathway in the abdominal 
area and significantly activated the inflammatory pathway in the genitals (in this 
specific case in the prostate, result of ex vivo bioluminescence analysis). These 
results are perfectly in line with the literature reports, in which prostate 
inflammation and metaplasia were detected in both mice and rats. 
Bisphenol A did not produce a significant activation in both the areas and in the ex 
vivo analysis, again in agreement with in silico/in vitro results. 
The lack of ER activation of estradiol in the genital area was possibly due to oral 
administration of the compound in drinking water. This compound exerts a potent 
adverse effect in toxicological studies when administered by injection. 
Several works in the literature made a correlation between in vitro and in vivo 
experiments. Sonneveld et al., established a good correlation between in vitro ERα-
CALUX and in ovariectomized test in young rats by scoring the vaginal 
cornification (Allen-Doisy test) [31]. Nevertheless, the plausibility of the in vivo 
model, has some limitations including a lack of certainty regarding the adequacy of 
animal species to the treatments (its sensitivity to the treatments), the life stages of 
animals; a lack of correlation between the mechanistic of action, that are diagnostic 
or predictive of endocrine disrupting activity, and apical response observed in vivo, 
that is the adverse outcomes [32]. In the last period new in vivo approach based on 
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transgenic mouse model have been generated to measure estrogen receptor (ER) 
transcriptional activity in living organisms [33]. 
From our results, in silico approach emerges as a computational methodology for 
the evaluation of the ER affinity (prioritization of assessment) of a large number of 
molecules. During a safety evaluation process, the molecules that show the lowest 
affinities should in principle be disregarded and the attention should be focused on 
the molecules that show the highest affinities. 
While the in silico screening based on the calculation of Ki cannot be used as a 
stand-alone procedure due to its intrinsic lack of biological meaning, it can be 
successfully used as a first prioritizing step in a tier approach. The second 
mandatory check for the in silico positive hits should be an in vitro evaluation 
procedure, in which the affinity of the positive hits is measured through a reference 
cellular assay. Then integrating the time variable in the evaluation of the potency 
and efficacy the tested compounds could be classified as ED or no-ED as obtained 
in our experiment. While the in vivo experiment highlighted that potent estrogenic 
compound, as zearalenone, could also raise concern for the activation of other 
toxicological pathway such as the inflammatory ones. 
We are aware that this indication of procedure must be evaluated on dozens of 
molecules whose in vivo activity is already known before arriving at its use to 
predict the possible activity of ED of unknown molecules, but we think that this 
approach deserves to be implemented. 
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Table 8. Summary of results relevant for estrogen receptor. The table shows the result of each chemical along the 
three different methodologies, where the chemical was able to interact within each system. Estradiol, as expected, 
ZEA were the strongest estrogen like compound in all assays (symbol X) except the boxes containing the symbol 
“- “. BPA showed positive results in silico and in vitro, while not statistical significant or controversial results were 
in the animal assays (“- “or +/-). 
Summary of results relevant for estrogen receptor 
Compound In silico 
model 
in vitro 
bioluminescence 
imaging 
In vivo bioluminescence imaging 
Genital area Abdominal area 
 hERα ERα ERE-Luc NFKB-Luc ARE-
Luc 
ERE-Luc NFKB-
Luc 
ARE-
Luc 
E2 X X +/- - +/- X - - 
ZEA X X +/- X 
(prostate) 
+/- X X - 
BPA X X +/- +/- 
(testis) 
+/- - - - 
DES X X 
GEN X X 
4-NP X - 
MXC X X 
VCZ X - 
DEPH X - 
 
E2 = 17β-estradiol; ZEA = zearalenone; BPA = bisphenol A; DES= diethylstilbestrol; GEN = 
genistein; 4-NP = 4-Nonylphenol; VCZ = vinclozolin; MXC = Methoxychlor; DEHP = Bis(2-
ethylhexyl) phthalate; X = interaction with receptor (p < 0.05); - =, no interaction or p > 0.05; 
Trend = +/- not statistically significant 
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APPENDIX A 
 
 
 
Figures and table of LC-MS analysis of samples from in vitro experiment. 
Figure 1A, 1B, 1C represent the chromatograms of determination of analytes 
(bisphenol A, zearalenone, genistein) from the medium. 
 
 
 
 
 
  
 
 
 
Figure 1A. example of LC-MS / MS trace of BPA extracted from the ID1sample. 
A: presence of the analyte (405 pg./µl, or 10-6M) (indicated with red arrow); B 
and C: absence of analyte (indicated with blue arrow); D: internal standard 
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Figure 1B example of LC-MS / MS trace of Genistein extracted from the ID2 
sample. B: presence of the analyte (130 pg./µl or 10-6M) (indicated with red 
arrow); A and C: absence of analyte (indicated with blue arrow); D: internal 
standard 
 
Figure 1C.  example of LC-MS / MS trace of Zearalenone extracted from the ID3 
sample. C: presence of the analyte (488 pg./µl or 10-6M) (indicated with red 
arrow); A and B: absence of analyte (indicated with blue arrow); D: internal 
standard 
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Summary of quantification of Bisphenol A, Zearalenone and Genistein n characterized 
in the cleaned medium(control) and in medium cell conditioning 
 
Table A) characterization of BPA in sample extracted from the medium and medium cell conditioning at 6 
hours  
 
 
samples 6 hours  
     
 
sample  treatment- 20.6.2018 pg/µl mean  DV STD t-test 6hours  t-test 6hours-
48hours only 
MEDIUM 
BPA  
31 only MEDIUM 1a 103 
93 6 
  
33 only MEDIUM 2a 90   
0.000 
35 only MEDIUM 3a 92   
37 only MEDIUM 4a 88   
39 only MEDIUM 5a 89   
71  MEDIUM COND 1a 127 
124 5 
  t-test 6hours-
48hours MEDIUM 
cond  73  MEDIUM COND 2a 127   
75  MEDIUM COND 3a 125   
0.164 77  MEDIUM COND 4a 126   
79  MEDIUM COND 5a 116 0.000019 
 
 
Table B) characterization of BPA in sample extracted from the medium and medium cell conditioning at 
48 hours 
 
 
samples 48 hours 
    
 
sample treatment- 22.6.2018 pg/µl mean DV STD t test 48 hours 
BPA 
131 only MEDIUM 1a 155 
134 13 
 
133 only MEDIUM 2a 123 
 
135 only MEDIUM 3a 123 
 
137 only MEDIUM 4a 131 
 
139 only MEDIUM 5a 138 
 
171 MEDIUM COND 1a 108 
159 51 
 
173 MEDIUM COND 2a 192 
 
175 MEDIUM COND 3a 218 
 
177 MEDIUM COND 4a 104 
 
179 MEDIUM COND 5a 174 0.313 
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Table C) characterization of genistein in sample extracted from the medium and medium cell 
conditioning at 6 hours 
 
 
samples 6 hours  
     
 
sample  treatment- 20.6.2018 pg/µl mean  DV STD t-test 6 hours  t-test 6hours-
48hours only 
MEDIUM 
GENI 
21 only MEDIUM 1a 210 
205 18 
  
23 only MEDIUM 2a 198   
0.413 
25 only MEDIUM 3a 177   
27 only MEDIUM 4a 219   
29 only MEDIUM 5a 221   
61  MEDIUM COND 1a 220 
216 12 
  T test 6hours-
48hours MEDIUM 
cond  63  MEDIUM COND 2a 219   
65  MEDIUM COND 3a 233   
0.286 67  MEDIUM COND 4a 206   
69  MEDIUM COND 5a 202 0.293318 
 
 
Table D) characterization of genistein in sample extracted from the medium and medium cell 
conditioning at 48 hours  
 
 
samples 48 hours  
    
 
sample  treatment- 22.6.2018 pg/µl mean  DV STD t test 48 hours  
GENI 
121 only MEDIUM 1a 196 
193 26 
  
123 only MEDIUM 2a 213   
125 only MEDIUM 3a 153   
127 only MEDIUM 4a 217   
129 only MEDIUM 5a 186   
161  MEDIUM COND 1a 220 
243 51 
  
163  MEDIUM COND 2a 281   
165  MEDIUM COND 3a 309   
167  MEDIUM COND 4a 228   
169  MEDIUM COND 5a 179 0.086 
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Table E) characterization of zearalenone in sample extracted from the medium and medium cell 
conditioning at 6 hours  
 
 
samples 6 hours  
     
 
sample  treatment- 20.6.2018 pg/µl mean  DV STD t-test 6hours   t-test 6hours-
48hours only 
MEDIUM 
ZEA 
11 only MEDIUM 1a 212 
226 89 
  
13 only MEDIUM 2a 247   
0.095 
15 only MEDIUM 3a 159   
17 only MEDIUM 4a 367   
19 only MEDIUM 5a 147   
51  MEDIUM  COND 1a 133 
126 13 
  t-test 6hours-
48hours MEDIUM 
cond  53  MEDIUM  COND 2a 135   
55  MEDIUM  COND 3a 109   
0.036 57  MEDIUM  COND 4a 117   
59  MEDIUM  COND 5a 137 0.037 
 
 
 
Table F) characterization of zearalenone in sample extracted from the medium and medium cell 
conditioning at 48 hours   
 
samples 48 hours  
    
 
sample  treatment- 22.6.2018 pg/µl mean  DV STD  t-test 48 hours  
ZEA 
111 only MEDIUM 1a 187 
149 22 
  
113 only MEDIUM 2a 133   
115 only MEDIUM 3a 133   
117 only MEDIUM 4a 141   
119 only MEDIUM 5a 153   
151  MEDIUM  COND 1a 93 
99 21 
  
153  MEDIUM  COND 2a 128   
155  MEDIUM  COND 3a 104   
157  MEDIUM  COND 4a 98   
159  MEDIUM  COND 5a 69 0.006 
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Summary of quantification of Bisphenol A, Zearalenone  and 
Genistein in cells extracts of MCF7 subclone B17  
 
Table F) characterization of BPA in sample extracted from MCF7 pellet 
 
samples 6 hours  
treatment 20.6.18  
ng/camp mean  DV STD 
t-test  
6hours-
48hours  
BPA  
96 MCF7 pellet  1 BPA 6h   0.51 
0.46 0.09 
  
97 MCF7 pellet  2 BPA 6h   0.36   
98 MCF7 pellet  3 BPA 6h   0.57   
99 MCF7 pellet  4 BPA 6h  0.39   
100 MCF7 pellet  5 BPA 6h   0.45   
 
samples 48 hours  treatment 22.6.18  ng/camp mean  DV STD   
BPA  
196 MCF7 pellet  1 BPA 48h  0.21 
0.47 0.16 
  
197 MCF7 pellet  2 BPA 48h  0.50   
198 MCF7 pellet  3 BPA 48h  0.55   
199 MCF7 pellet  4 BPA 48h   0.65   
200 MCF7 pellet  5 BPA 48h   0.47 0.864 
 
Table G) characterization of genistein in sample extracted from MCF7 pellet 
         
 
samples 6 hours  
treatment 20.6.18  
ng/camp mean  DV STD 
t-test 
 6hours-
48hours  
GENI 
91 MCF7 pellet  1 GENI 6h 2.50 
3.04 0.55 
  
92 MCF7 pellet  2 GENI 6h  3.44   
93 MCF7 pellet  3 GENI 6h  2.72   
94 MCF7 pellet  4 GENI 6h  3.79   
95 MCF7 pellet  5 GENI 6h  2.76   
 samples 48 hours  treatment 22.6.18  ng/camp mean  DV STD   
GENI 
191 MCF7 pellet 1 GENI 48h  4.91 
4.76 0.59 
  
192 MCF7 pellet  2 GENI 48h  4.19   
193 MCF7 pellet  3 GENI 48h  4.43   
194 MCF7 pellet  4 GENI 48h   5.71   
195 MCF7 pellet  5 GENI 48h   4.55 0.001 
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Table H) characterization of zearalenone in sample extracted from MCF7 pellet   
 
 
 
samples 6 hours  
treatment 20.6.18  
ng/camp mean  DV STD 
t-test 
6hours-
48hours  
ZEA 
86 MCF7 pellet  1 ZEA 6h   1.78 
1.74 0.49 
  
87 MCF7 pellet  2 ZEA 6h   1.18   
88 MCF7 pellet  3 ZEA 6h   2.52   
89 MCF7 pellet  4 ZEA 6h  1.68   
90 MCF7 pellet  5 ZEA 6h   1.54   
 samples 48 hours  treatment 22.6.18 ng/camp mean  DV STD   
ZEA 
186 MCF7 pellet  1 ZEA 48h  2.20 
2.45 0.59 
  
187 MCF7 pellet  2 ZEA 48h  2.17   
188 MCF7 pellet  3 ZEA 48h  3.43   
189 MCF7 pellet  4 ZEA 48h   1.92   
190 MCF7 pellet  5 ZEA 48h   2.51 0.073 
 
